2nd Inflammatory Skin Disease Summit
The Translational Revolution

November 16–19, 2016
The New York Academy of Medicine, NY, USA

MEETING PROGRAM
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>WELCOMING WORDS</td>
<td>2</td>
</tr>
<tr>
<td>GENERAL INFORMATION</td>
<td>3</td>
</tr>
<tr>
<td>REGISTRATION</td>
<td>9</td>
</tr>
<tr>
<td>NETWORKING EVENTS</td>
<td>10</td>
</tr>
<tr>
<td>SCIENTIFIC PROGRAM INFORMATION</td>
<td>12</td>
</tr>
<tr>
<td>SCIENTIFIC PROGRAM</td>
<td>18</td>
</tr>
<tr>
<td>ACCEPTED ABSTRACTS</td>
<td>26</td>
</tr>
<tr>
<td>EDUCATIONAL GRANT ACKNOWLEDGEMENT</td>
<td>50</td>
</tr>
<tr>
<td>COMMERCIAL EXHIBITION/SPONSORSHIP</td>
<td>51</td>
</tr>
<tr>
<td>INDUSTRY SUPPORTED SESSIONS</td>
<td>52</td>
</tr>
</tbody>
</table>

Jointly provided by the Kimberly and Eric J. Waldman Mount Sinai Department of Dermatology and the Austrian Academy of Sciences.
Welcome Words

Dear participants,

It is an honor and our great pleasure to welcome you to the “2nd Inflammatory Skin Disease Summit 2016 – The Translational Revolution”!

In the past decade, we have experienced a veritable breakthrough in the management of inflammatory skin diseases, which were previously lacking satisfactory treatments. This revolution is particularly evident with the introduction of novel targeted therapies for key inflammatory skin diseases such as psoriasis, atopic dermatitis, and an increasing number of other inflammatory conditions. This exciting development stems from a growing knowledge of pathogenic pathways, and the advent of new technologies that are directly applicable to human biologic substrates. These ultimately led to the development of narrow therapeutics, and to their testing in clinical trials, further amplifying our current disease understanding.

Two years after a very successful first summit in 2014 in Vienna, Austria, we decided to continue this path with organizing a second “Inflammatory Skin Disease Summit” which will directly address and describe these new developments. We aim to deliver an outstanding meeting to our participants including plenary lectures given by world leaders in their fields, poster sessions, three sessions of oral presentations from selected abstracts and, most importantly, a vivid discussion in the lecture hall, in front of the many posters, and during our social events.

We want to thank all participants who have decided to join us for what we hope will be a scientifically most stimulating event, all invited speakers and poster presenters for sharing their work with us, our generous sponsors, and all the helping hands making this meeting possible. We would also like to thank the Austrian Academy of Sciences and the Kimberly and Eric J. Waldman Mount Sinai Department of Dermatology for their patronage.

We very much hope that you will enjoy this symposium in the heart of New York!

With kind regards,

Emma Guttman, MD, PhD  James G. Krueger, MD, PhD  Georg Stingl, MD  Patrick M. Brunner, MD
General Information

**ORGANIZING COMMITTEE**

Emma Guttman, MD, PhD  
Professor and Vice-Chair  
Dpt. of Dermatology  
Icahn School of Medicine at Mount Sinai  
New York, NY, United States

James G. Krueger, MD, PhD  
Director, Milstein Medical Research Program  
Senior Attending Physician  
D. Martin Carter Professor in Clinical Investigation  
Laboratory for Investigative Dermatology  
The Rockefeller University  
New York, NY, United States

Georg Stingl, MD  
Professor and Chair  
Department of Dermatology  
Medical University of Vienna  
Vienna, Austria

Patrick M. Brunner, MD  
Laboratory for Investigative Dermatology  
The Rockefeller University  
New York, NY, United States

**GENERAL ORGANIZATION AND REGISTRATION**

Office of CME, Icahn School of Medicine at Mount Sinai  
One Gustave L. Levy Place, Box 1193  
New York, NY 10029  
Phone: 212-731-7950  
Fax: 646-537-9203  
Email: cme@mssm.edu

**Abstract Submission:**

Mondial Congress & Events  
Operngasse 20b  
1040 Vienna, Austria  
Phone: +43 1 58804 -158  
Email: isds2016@mondial-congress.com
MEETING LOCATION
The New York Academy of Medicine
1216 Fifth Avenue (at 103rd Street)
New York, NY 10029
212-822-7200
www.nyam.org

HOW TO GET TO THE MEETING
The Academy is located at the corner of Fifth Avenue and 103rd Street. The entrance is on 103rd Street.

BY SUBWAY
Take the 6 train to 103rd Street. Walk west on 103rd Street; after crossing Park Avenue, turn right and walk a few yards, and then turn left onto the path through the garden of Carver Houses to Madison Avenue. Continue west on 103rd Street almost to Fifth Avenue. The entrance to the Academy is on 103rd Street. Check the MTA website for updates on planned service changes.

FROM 42ND STREET/TIMES SQUARE:
Take Shuttle Train to 42nd / Street Grand Central and transfer to the #6 Train (Uptown) to 103rd Street.

BY BUS, FROM SOUTH OF 103RD STREET:
On Madison Avenue, take a northbound M1, M2, M3, or M4 bus to 103rd Street. Walk west on 103rd Street almost to Fifth Avenue. The entrance to the Academy is on 103rd Street.

BY BUS, FROM NORTH OF 103RD STREET:
On Fifth Avenue, take a southbound M1, M2, M3, or M4 bus to 103rd Street. The entrance to the Academy is on 103rd Street, on the southeast corner of the intersection of 103rd Street and Fifth Avenue.

FROM GRAND CENTRAL STATION/GRAND CENTRAL TERMINAL:
Exit Grand Central Station and Terminal on 42nd Street at Vanderbilt Avenue. Walk one short block west to Madison Avenue and take the M1, M2, M3 or M4 (Northbound) bus 103rd Street. Walk west on 103rd Street almost to Fifth Avenue. The entrance to the Academy is on 103rd Street.
FROM METRO NORTH/125TH STREET AND PARK AVENUE:
Exit the station and take the M101 bus on Lexington Avenue southbound to East 102nd Street. Walk three blocks east to Fifth Avenue and proceed north to 103rd Street.

FROM PORT AUTHORITY BUS TERMINAL:
Exit the terminal at the West 42nd Street exit. Proceed to Eighth Avenue and take the M42 Bus east to Madison Avenue. Transfer to the M1, M2, M3 or M4 (Northbound) bus 103rd Street. Walk west on 103rd Street almost to Fifth Avenue. The entrance to the Academy is on 103rd Street.

FROM PENNSYLVANIA STATION:
Exit the terminal at the West 33rd Street exit. Proceed to Eighth Avenue and take the M42 Bus east to Madison Avenue. Transfer to the M1, M2, M3 or M4 (Northbound) bus 103rd Street. Walk west on 103rd Street almost to Fifth Avenue. The entrance to the Academy is on 103rd Street.

BY CAR, FROM SOUTH OF 96TH STREET:
From the FDR Drive North, take the 96th Street exit. Turn left onto 96th Street, and drive straight until Madison Avenue. Turn right on Madison, and drive north to 103rd Street. Turn left, and the Academy is at the end of the block on the south side of the street.

BY CAR, FROM NORTH OF 96TH STREET:
From the FDR Drive South, take the 96th Street exit. Turn right onto E. 96th Street, and drive straight until Madison Avenue. Turn right on Madison, and drive north to 103rd Street. Turn left, and the Academy is at the end of the block on the south side of the street.

PARKING
There are several public parking lots in the area, including the following:

- Manhattan Parking 10 East 102nd St. (Between Fifth and Madison Aves)
- Standard Parking 14 East 103rd St. (Between Fifth and Madison Aves)
- Merit Parking 12 East 107th St. (Between Fifth and Madison Aves)

COAT ROOM
A coat room and luggage storage facilities will be available across from the Registration Area on the ground floor.
SMOKING AREA
Thank you for not smoking inside the meeting location. Please note: smoking is NOT permitted in front of the building. We ask that you cross the street or walk further down away from the main entrance.

WIFI
Free WiFi is available.
- Network: ECC
- Password: ecc45678

VENUE
1st Floor
- Entry Hall
- Hosack Hall
- Reception II
- President’s Gallery
- Men and Women’s Restrooms

Registration
Scientific Sessions
Speaker Ready Room
Beverage Area
2nd Floor
- Room 20
- Room 21
- Women’s Restroom

Satellite Symposium
Poster Area
3rd Floor
- Library Reading Room
- Periodical Reading Room
- Men and Women’s Restrooms

Exhibition & Poster Area
Poster Area

4th Floor
- Room 440

Poster Area
Registration

The registration area is located in the entry hall on the ground floor. The meeting staff will be pleased to help you with any inquiries. Please do not hesitate to approach the team members if there is anything they can do to make your stay more enjoyable.

REGISTRATION DESK HOURS

Wednesday, November 16, 2016  2:30 PM – 7:30 PM
Thursday, November 17, 2016  7:00 AM – 6:15 PM
Friday, November 18, 2016  7:30 AM – 4:00 PM
Saturday, November 19, 2016  7:30 AM – 6:00 PM

ONSITE REGISTRATION FEES

<table>
<thead>
<tr>
<th>Registration Fee</th>
<th>$ 500</th>
</tr>
</thead>
<tbody>
<tr>
<td>Students/Residents/Fellows*</td>
<td>$ 250</td>
</tr>
</tbody>
</table>

*Students/Residents/Fellows: Attend full 4 day conference and your registration fee will be refunded (less a $25.00 administrative fee). Attendance will be verified.

The participants’ registration fee includes:

- Admission to all scientific sessions
- Admission to scientific poster area and commercial exhibition
- Summit materials (meeting bag, final program, abstract book)
- CME Certificate or Certificate of Attendance
- Continental Breakfast, Coffee Breaks, Lunch
- Opening Ceremony & Welcome Reception from 7:30 PM to 9:30 PM on Wednesday, November 16, 2016
- Reception on from 6:15 PM to 9:00 PM on Thursday, November 17, 2016
- Industry supported sessions (satellite symposia)

PAYMENT DETAILS

Please note that all onsite payments need to be made in cash or by credit card (Visa, MasterCard, American Express will be accepted) in United States Dollars (USD) only. We cannot accept traveler’s checks, other credit cards, Euro checks or other currencies.
Networking Events

WELCOME RECEPTION & POSTER VIEWING
Date and Time: Wednesday, November 16, 2016 | 7:30 PM – 9:30 PM
Location: 3rd Floor, Library Reading Room – Exhibition & Poster Area

RECEPTION & POSTER VIEWING
Date and Time: Thursday, November 17, 2016 | 6:15 PM – 9:00 PM
Location: 3rd Floor, Library Reading Room – Exhibition & Poster Area

Enjoy the Receptions in the Exhibition & Poster Area with drinks, hors d'oeuvres and cocktail stations

POSTER VIEWING
Wednesday, November 16, 2016 7:30 PM – 9:30 PM
Thursday, November 17, 2016 7:00 AM – 9:00 PM
Friday, November 18, 2016 7:30 AM – 5:30 PM
Saturday, November 19, 2016 7:30 AM – 6:00 PM

Poster Locations:
2nd Floor, Room 21 – Poster Area
3rd Floor, Library Reading Room – Exhibition & Poster Area
3rd Floor, Periodical Reading Room – Poster Area
Floor, Room 440 – Poster Area

CONTINENTAL BREAKFAST
Coffee, tea, juice, water, fruit, bagels and pastries will be offered during continental breakfast.

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, November 17</td>
<td>7:00 AM – 8:00 AM</td>
<td>3rd Floor – Reading room</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2nd Floor – Hallway</td>
</tr>
<tr>
<td>Friday, November 18</td>
<td>7:30 AM – 8:30 AM</td>
<td>3rd Floor – Reading room</td>
</tr>
<tr>
<td>Saturday, November 19</td>
<td>7:30 AM – 8:30 AM</td>
<td>3rd Floor – Reading room</td>
</tr>
</tbody>
</table>
LUNCH

Lunch will be provided at following times and in the locations listed below:

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, Nov 17</td>
<td>12:45 PM - 2:15 PM</td>
<td>3rd Floor – Reading room</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2nd Floor – Hallway</td>
</tr>
<tr>
<td>Friday, Nov 18</td>
<td>12:15 PM - 1:45 PM</td>
<td>1st Floor – Hosack Hall</td>
</tr>
<tr>
<td>Saturday, Nov 19</td>
<td>12:00 PM - 12:15 PM</td>
<td>1st Floor – Hosack Hall</td>
</tr>
</tbody>
</table>

COFFEE BREAKS

Refreshments will be offered during coffee breaks.
Scientific Program Information

OPENING HOURS – SPEAKERS’ READY ROOM
The Speakers’ Ready Room is located in the Reception II room on the first floor. The hours of operation are as follows:

- Wednesday, November 16, 2016: 2:30 PM – 6:45 PM
- Thursday, November 17, 2016: 7:00 AM – 6:15 PM
- Friday, November 18, 2016: 7:30 AM – 4:00 PM
- Saturday, November 19, 2016: 7:30 AM – 5:45 PM

PRESENTATION GUIDELINES

1. Please locate the session prior to your presentation time. Please be at the session room at least 15 minutes before the start of the session.
2. Speakers should view/check their PowerPoint presentations at the Speakers’ Ready Room (Reception II) at least two hours prior to the start of the respective session. For sessions starting at the beginning of the next day, the PowerPoint should be delivered the previous day.
3. Speakers are required to provide their USB drives containing their PowerPoint presentation to the AV technician in the main meeting room.

In order to avoid any delays, speakers are kindly requested to hand in their presentations on USB. We strongly encourage you not to bring your own laptop. Presentation should be on USB.

SESSION CHAIRPERSON GUIDELINES

Please locate your session room in due time. Please arrive at the session room at least 15 minutes prior to the start of the session. We may remind you that speakers need to strictly stick to the time schedule.

POSTERS

The poster areas are located in four rooms. Each poster will be displayed for the entire duration of the summit. Posters have to be mounted on Wednesday, November 16, 2016 between 1:00 – 2:30 PM. Please attach the poster to the board with the corresponding poster placement number and remove it on Saturday, November 19, 2016 until 6:30pm.
ABSTRACT BOOK
A printed abstract book will be provided in your congress bag. Moreover, the abstracts will be published in “Experimental Dermatology.”

TRAVEL FELLOWSHIPS
Travel Fellowships need to be picked up at the registration desk on Saturday, November 19, 2016 after 10:00 am.

INVITED SPEAKERS

Angela Christiano, PhD, FACMG
Professor
Dpt. of Dermatology
Columbia University
College of Physicians & Surgeons
New York, NY, USA

Rachael A. Clark, MD, PhD
Associate Professor
Dpt. of Dermatology
Harvard Medical School
Boston, MA, USA

Kevin D. Cooper, MD
Professor and Chair
Dpt. of Dermatology
Case Western Reserve University
Cleveland, OH, USA

Lars E. French, MD
Professor and Chair
Dpt. of Dermatology
University of Zurich
Zurich, Switzerland

Richard Gallo, MD, PhD
Professor and Chair
Dpt. of Dermatology
University of California, San Diego
San Diego, CA, USA

Michel Gilliet, MD
Professor and Chair
Dpt. of Dermatology
University of Lausanne
Lausanne, Switzerland

Raphaela T. Goldbach-Mansky, MD, MHS
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health
Bethesda, MD, USA

Emma Guttman, MD, PhD
Professor and Vice-Chair
Dpt. of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY, USA

John E. Harris, MD, PhD
Associate Professor
Dpt. of Medicine,
Dermatology Division
University of Massachusetts
Worcester, MA, USA

Michael D. Howell, PhD
MedImmune
Gaithersburg, MD, USA
Kenji Kabashima, MD, PhD  
Professor and Chair  
Dpt. of Dermatology  
Kyoto University  
Kyoto, Japan  

Eynav Klechevsky, PhD  
Assistant Professor, Pathology and Immunology  
Washington University School of Medicine  
St. Louis, MO, USA  

Heidi Kong, MD, MHSc  
Center for Cancer Research  
National Cancer Institute  
Dermatology Branch  
National Institutes of Health  
Bethesda, MD, USA  

Thomas Krieg, MD, FRCP  
Professor and Chair  
Dpt. of Dermatology & Venereology  
University of Cologne  
Cologne, Germany  

James G. Krueger, MD, PhD  
Professor  
Laboratory for Investigative Dermatology  
The Rockefeller University  
New York, NY, USA  

Thomas S. Kupper, MD  
Professor and Chair  
Dpt. of Dermatology  
Harvard Medical School  
Boston, MA, US  

Mark Lebwohl, MD  
Professor and Chair  
Dpt. of Dermatology  
Icahn School of Medicine at Mount Sinai  
New York, NY, USA  

Donald Y. M. Leung, PhD, MD  
Professor and Chair  
Div. of Pediatric Allergy and Immunology  
Dpt. of Pediatrics  
National Jewish Health  
Denver, CO, USA  

Thomas Luger, MD  
Professor and Chair  
Dpt. of Dermatology  
University of Muenster  
Muenster, Germany  

Marcus Maurer, MD  
Professor  
Dpt. of Dermatology, Allergology and Venereology  
Humboldt University  
Berlin, Germany  

Keisuke C. Nagao, MD, PhD  
Center for Cancer Research  
National Cancer Institute  
Dermatology Branch  
National Institutes of Health  
Bethesda, MD, USA  

Alexander Navarini, MD, PhD  
Professor of Immunodermatology  
Dpt. of Dermatology  
University of Zurich  
Zurich, Switzerland
Frank O. Nestle, MD
Global Head of Immunology Therapeutic Research Area
Chief Scientific Officer North America at Sanofi
Cambridge, MA, USA

John J. O’Shea
Scientific Director
Molecular Immunology and Inflammation Branch
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health
Bethesda, MD, USA

Amy S. Paller, MD
Professor and Chair
Dpt. of Dermatology
Northwestern University
Feinberg School of Medicine
Chicago, IL, USA

Virginia Pascual, MD
Director
Center for Inflammation and Autoimmune Diseases
Center for Personalized Medicine
Baylor Institute for Immunology Research
Dallas, TX, USA

Aimee S. Payne, MD, PhD
Associate Professor
Dpt. of Dermatology
University of Pennsylvania
Philadelphia, PA, USA

Martin Roecken, MD
Professor and Chair
Dpt. of Dermatology
Eberhard Karls University
Tuebingen, Germany

Misha A. Rosenbach, MD
Assistant Professor
Dpt. of Dermatology
University of Pennsylvania
Philadelphia, PA, USA

Jonathan I. Silverberg, MD, PhD, MPH
Assistant Professor
Dpt. of Dermatology
Northwestern University
Feinberg School of Medicine
Chicago, IL, USA

John R. Stanley, MD
Professor of Dermatology
Dpt. of Dermatology
University of Pennsylvania
Philadelphia, PA, USA

Georg Stingl, MD
Professor and Chair
Department of Dermatology
Medical University of Vienna
Vienna, Austria

Diane M. Thiboutot, MD
Professor of Dermatology
Vice-Chair for Research for Dermatology
Penn State University College of Medicine
Hershey, PA, USA

George D. Yancopoulos, MD, PhD
President, Research Laboratories & CSO
Regeneron Pharmaceuticals
Pharmaceuticals
Tarrytown, NY, USA
SESSION CHAIRS

Andrew F. Alexis, MD, MPH
Associate Professor and Chair
Dpt. of Dermatology
St. Luke’s-Roosevelt Hospital
New York, NY, USA

Christine Bangert, MD
Dpt. of Dermatology
Medical University of Vienna
Vienna, Austria

Lisa A. Beck, MD
Professor
Dpt. of Dermatology
University of Rochester Medical Center
Rochester, NY, USA

Keith Choate, MD, PhD
Associate Professor
Dpt. of Dermatology
Yale University School of Medicine
New Haven, CT, USA

David E. Cohen, MD, MPH
Professor of Dermatology
Dpt. of Dermatology
New York University, School of Medicine
New York, NY, USA

Lawrence F. Eichenfield, MD
Chief of Pediatric and Adolescent Dermatology
University of California, San Diego
San Diego, CA, USA

Kilian Eyerich, MD
Assistant Professor
Dpt. of Dermatology
Technical University of Munich
Munich, Germany

Stefanie Eyerich, PhD
Helmholtz Research Group
Technical University of Munich
Munich, Germany

Zahi A. Fayad, PhD
Professor and Chair
Translational and Molecular Imaging Institute
Icahn School of Medicine at Mount Sinai
New York, NY, USA

Amos Gilhar, MD
Professor
Technion – Israel Institute of Technology
Haifa, Israel

Richard D. Granstein, MD
Professor and Chairman
Dpt. of Dermatology
Weill Cornell Medical College
New York, NY, USA

Johann Gudjonsson, MD, PhD
Assistant Professor
Dpt. of Dermatology
University of Michigan
Ann Arbor, MI, USA

Emmilia Hodak, MD
Professor and Chair
Dpt. of Dermatology
Beilinson Hospital
Rabin Medical Center
Tel Aviv, Israel

Sergio Lira, MD, PhD
Professor and Director
Immunology Institute
Icahn School of Medicine at Mount Sinai
New York, NY, USA
Michelle Lowes, MD, PhD
Associate Professor
Montefiore Medical Center
New York, NY, USA

Avi Ma’ayan, PhD
Professor
Pharmacological Sciences
Icahn School of Medicine at Mount Sinai
New York, NY, USA

Miriam Merad, MD, PhD
Professor and Director
Immunology Institute
Icahn School of Medicine at Mount Sinai
New York, NY, USA

Daniel Mimouni, MD
Associate Professor
Dpt. of Dermatology
Beilinson Hospital
Rabin Medical Center
Tel Aviv, Israel

Robert Modlin, MD
Professor and Chair
Dpt. of Dermatology
University of California, Los Angeles
Los Angeles, CA, USA

Brian J. Nickoloff, MD, PhD
Senior Medical Fellow
Eli Lilly & Company
Carmel, IN, USA

David A. Norris, MD
Professor and Chairman
Dpt. of Dermatology
University of Colorado School of Medicine
Denver, CO, USA

Hugh Sampson, MD
Professor and Director
Jaffe Food Allergy Institute
Icahn School of Medicine at Mount Sinai
New York, NY, USA

Mayte Suárez-Fariñas, PhD
Associate Professor
Dpt. of Genetics and Genomics Science
Dpt. of Population Health Science and Policy
Icahn School of Medicine at Mount Sinai
New York, NY, USA

Claudia Traidl-Hoffmann, MD
Professor and Chair
Institute of Environmental Medicine
German Research Center for Environmental Health, UNIKA-T
Augsburg, Germany

Nicole L. Ward, PhD
Associate Professor
Dpt. of Dermatology
Case Western Reserve University
Cleveland, OH, USA

ORAL ABSTRACT PRESENTERS
Yuki M.F. Andersen, MD
Samuel J. Balin, MD, PhD
Shreya Bhattacharya, PhD
Patrick M. Brunner, MD
Jonathan Curry, MD
Christoph Ellebrecht, MD
Emma Guttmann, MD, PhD
Arup Indra, PhD
Felix Lauffer, MD
Lucie Mondoulet, PhD
Yumi Nonomura, MD
Verena Raker, PhD
Luis F. Santamaria-Babi, PhD
Susan Smith, PhD
Mayte Suárez-Fariñas, PhD
Scientific Program

WEDNESDAY, NOVEMBER 16, 2016

02.30 pm REGISTRATION OPENS

Opening
Chairs: Emma Guttman (New York, NY), Patrick M. Brunner (New York, NY)

03.30 pm – 03.45 pm Welcome address

03.45 pm – 04.00 pm Setting the stage
Georg Stingl (Vienna, Austria)

04.00 pm – 04.30 pm Inflammatory skin diseases – The technological revolution
James G. Krueger (New York, NY)

04.30 pm – 05.00 pm The skin immune system in health and disease
Thomas S. Kupper (Boston, MA)

05.00 pm – 05.15 pm BREAK

05.15 pm – 06.45 pm Sponsored afternoon symposium (see page 52)

06.45 pm – 07.30 pm Oral presentations from selected abstracts
Chairs: Amos Gilhar (Haifa, IL), Avi Ma‘ayan (New York, NY)

06.45 pm – 06.57 pm P074: A distinct molecular signature of interface dermatitis as determined by gene expression analysis combined with disease independent histological phenotyping
Felix Lauffer (Munich, Germany)

06.57 pm – 07.09 pm P126: The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk markers
Patrick M. Brunner (New York, NY)

07.09 pm – 07.21 pm P046: CD8+ polycytotoxic T cells are defined by natural killer cell receptors and exhibit antimicrobial activity against intracellular bacteria
Samuel J. Balin, Los Angeles, CA

07.30 pm – 09.30 pm RECEPTION AND POSTER VIEWING
THURSDAY, NOVEMBER 17, 2016

07.00 am – 08.00 am REGISTRATION AND CONTINENTAL BREAKFAST

08.00 am – 09.30 am Sponsored breakfast symposium (see pages 52-53)

Morning lectures
Chairs: Robert Modlin (Los Angeles, CA), Miriam Merad (New York, NY)

09.30 am – 10.00 am Innate immunity and dendritic cells
Michel Gilliet (Lausanne, Switzerland)

10.00 am – 10.30 am Antigen presentation in the skin
Keisuke C. Nagao (Bethesda, MD)

10.30 am – 11.00 am Dendritic cell subsets – Of mice and men
Eynav Klechevsky (St. Louis, MO)

11.00 am – 11.30 am COFFEE BREAK

Chairs: Johann Gudjonsson (Ann Arbor, MI), Claudia Traidl-Hoffmann (Augsburg, Germany)

11.30 am – 12.00 pm Skin T cells revisited
Rachael A. Clark (Boston, MA)

12.00 pm – 12.30 pm Lymphocyte identity crisis: genomic views
John O’Shea (Bethesda, MD)

12.30 pm – 12.45 pm BREAK

12.45 pm – 02.15 pm Satellite lunch symposium (see page 53)

Afternoon lectures
Chairs: Richard D. Granstein (New York, NY), Lawrence F. Eichenfield (San Diego, CA)

02.15 pm – 02.45 pm The microbiome of healthy and eczematous skin
Heidi Kong (Bethesda, MD)

02.45 pm – 03.15 pm Rosacea and AMPs
Richard Gallo (San Diego, CA)

03.15 pm – 03.45 pm Acne and hidradenitis
Diane M. Thiboutot (Hershey, PA)

03.45 pm – 04.15 pm Role of infections in inflammatory skin diseases
Donald Y. M. Leung (Denver, CO)
4.15 pm – 04.45 pm  COFFEE BREAK

_Chairs: Michelle Lowes (New York, NY), Hugh Sampson (New York, NY)_

04.45 pm – 05.15 pm  _The inflammasome and autoinflammation_
_Raphaela T. Goldbach-Mansky (Bethesda, MD)_

05.15 pm – 05.45 pm  _Skin inflammation by 3-dimensional imaging_
_Kenji Kabashima (Kyoto, Japan)_

05.45 pm – 06.15 pm  _Mediators of inflammation_
_Thomas Luger (Münster, Germany)_

06.15 pm – 09.00 pm  RECEPTION AND POSTER VIEWING
FRIDAY, NOVEMBER 18, 2016

07.30 am - 08.30 am  REGISTRATION AND CONTINENTAL BREAKFAST

Morning lectures
Chairs: Lisa A. Beck (Rochester, NY), David E. Cohen (New York, NY)

08.30 am - 09.00 am  Comorbidities in inflammatory skin diseases
Jonathan I. Silverberg (Chicago, IL)

09.00 am - 09.30 am  Psoriasis - State of the art mechanisms, targeted therapies and future developments
Frank O. Nestle (Cambridge, MA)

09.30 am - 10.00 am  Monocyte/myeloid cell dysfunction in psoriasis - relationship to comorbidity mechanisms
Kevin D. Cooper (Cleveland, OH)

10.00 am - 10.30 am  COFFEE BREAK

Chairs: Nicole L. Ward (Cleveland, OH), Keith Choate (New Haven, CT)

10.30 am - 11.00 am  Evolving concepts in atopic dermatitis and implications for targeted therapeutics
Emma Guttman (New York, NY)

11.00 am - 11.30 am  Translational potential for treatment of pediatric inflammatory skin diseases
Amy S. Paller (Chicago, IL)

11.30 am - 12.00 pm  Adverse cutaneous drug reactions - Clinical presentation and pathogenesis
Lars E. French (Zurich, Switzerland)

12.00 pm - 12.15 pm  BREAK

12.15 pm - 01.45 pm  Sponsored lunch symposium (see pages 53-54)

Afternoon lectures
Chairs: Andrew Alexis (New York, NY), David A. Norris (Denver, CO)

01.45 pm - 02.15 pm  Translational research in vitiligo - Launching a new era of targeted treatment
John E. Harris (Worcester, MA)
02.15 pm – 02.45 pm  Targeted therapies in alopecia areata  
Angela Christiano (New York, NY)

02.45 pm – 03.15 pm  Characterization of the autoantibody repertoire in pemphigus  
John R. Stanley (Philadelphia, PA)

03.15 pm – 03.45 pm  Targeted therapy for blistering disorders  
Aimee S. Payne (Philadelphia, PA)

03.45 pm – 04.00 pm  COFFEE BREAK

04.00 pm – 05.30 pm  Sponsored afternoon symposium (see page 54)
**SATURDAY, NOVEMBER 19, 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30 am – 08:30 am</td>
<td><strong>REGISTRATION AND CONTINENTAL BREAKFAST</strong></td>
</tr>
<tr>
<td>08:30 am – 10:00 am</td>
<td><strong>Sponsored breakfast symposium (see page 55)</strong></td>
</tr>
<tr>
<td>10.00 am – 10.30 am</td>
<td><strong>Inflammation and cancer – The two sides of the coin</strong></td>
</tr>
<tr>
<td></td>
<td>Martin Röcken (Tübingen, Germany)</td>
</tr>
<tr>
<td>10.30 am – 11.00 am</td>
<td><strong>Sarcoidosis and targeted therapeutics</strong></td>
</tr>
<tr>
<td></td>
<td>Misha A. Rosenbach (Philadelphia, PA)</td>
</tr>
<tr>
<td>11.00 am – 12.00 pm</td>
<td><strong>Oral presentations from selected abstracts</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Ralf Paus (Manchester, United Kingdom), Stefanie Eyerich (Munich, Germany)</td>
</tr>
<tr>
<td>11.00 am – 11.12 am</td>
<td>P122: Dupilumab progressively suppresses inflammation, reduces epidermal hyperplasia and increases epidermal barrier gene expression in atopic dermatitis (AD) skin</td>
</tr>
<tr>
<td></td>
<td>Emma Guttman (New York, NY)</td>
</tr>
<tr>
<td>11.12 am – 11.24 am</td>
<td>P087: Novel chimeric immunoreceptors for pemphigus vulgaris (PV) therapy</td>
</tr>
<tr>
<td></td>
<td>Christoph T. Ellebrecht (Philadelphia, PA)</td>
</tr>
<tr>
<td>11.24 am – 11.36 am</td>
<td>P048: Streptococcus pyogenes activation of circulating CLA+ T cells in guttate and chronic plaque psoriasis patients: IL-9 production dependence on time of flare, PASI, ASO levels, and relationship with IL-17 response</td>
</tr>
<tr>
<td></td>
<td>Luis F Santamaria-Babi (Barcelona, Spain)</td>
</tr>
<tr>
<td>11.36 am – 11.48 am</td>
<td>P111: The epithelial DLX3-dependent transcriptome regulates skin immune homeostasis</td>
</tr>
<tr>
<td></td>
<td>Shreya Bhattacharya (Bethesda, MD)</td>
</tr>
<tr>
<td>11.48 am – 12.00 pm</td>
<td>P018: Application of peanut protein on normal skin leads to tolerance whereas application on irritated skin leads to IgE sensitization</td>
</tr>
<tr>
<td></td>
<td>Lucie Mondoulet (Montrouge, France)</td>
</tr>
<tr>
<td>12.00 pm – 12.15 pm</td>
<td><strong>BREAK</strong></td>
</tr>
</tbody>
</table>
12.15 pm - 01.45 pm  **Oral presentations from selected abstracts**  
*Chairs: Kilian Eyerich (Munich, Germany), Christine Bangert (Vienna, Austria)*

12.15 pm - 12.27 pm  
P107: Altered composition of epidermal lipids correlates with *Staphylococcus aureus* colonization status in adult Atopic Dermatitis subjects  
*Arup Indra (Corvallis, OR)*

12.27 pm - 12.39 pm  
P021: Association between atopic dermatitis and autoimmune disease in adults  
*Yuki M.F. Andersen (Hellerup, Denmark)*

12.39 pm - 12.51 pm  
P004: Clinical and Histologic Patterns of Dermatologic Toxicity from Immune Checkpoint Blockade Therapy  
*Jonathan Curry (Houston, TX)*

12.51 pm - 01.03 pm  
P058: Immunological analysis of metastatic melanoma patients treated with nivolumab; is Th9 cell subset a possible biomarker of treatment efficacy?  
*Yumi Nonomura (Kyoto, Japan)*

01.03 pm - 01.15 pm  
P125: Anti-inflammatory activity of a bacterial small molecule product derives from Aryl Hydrocarbon Receptor activation  
*Susan Smith (Durham, NC)*

01.15 pm - 01.27 pm  
P127: Precision medicine in psoriasis: Machine learning and proteomics join forces to develop a blood-based test to predict response to tofacitinib or Etanercept in psoriasis patients  
*Mayte Suárez-Fariñas (New York, US)*

01.27 pm - 01.39 pm  
P012: Improvement of DC vaccination strategies: Identification of a stable and migratory subset of IL-10 modulated dendritic cells.  
*Verena Raker (Mainz, Germany)*

---

**Afternoon lectures**

*Chairs: Daniel Mimouni (Tel Aviv, Israel), Sergio Lira (New York, NY)*

01.45 pm - 02.15 pm  
**Scleroderma**  
*Thomas Krieg (Cologne, Germany)*
02.15 pm – 02.45 pm  Lupus – Pathogenic and therapeutic advances  
Virginia Pascual (Dallas, TX)

02.45 pm – 03.15 pm  Chronic urticaria and IgE targeting  
Marcus Maurer (Berlin, Germany)

03.15 pm – 03.45 pm COFFEE BREAK

Chairs: Brian J. Nickoloff (Carmel, IN), Zahi A. Fayad (New York, NY)

03.45 pm – 04.15 pm  Chances and hurdles of investigator initiated trials  
Alexander Navarini (Zurich, Switzerland)

04.15 pm – 04.45 pm  Unmet needs – Defining research frontiers  
Michael D. Howell (Gaithersburg, MD)

04.45 pm – 05.15 pm  The translational revolution – Implications for the health care system  
Mark Lebwohl (New York, NY)

05.15 pm – 05.45 pm  From target discovery to therapeutic development  
George D. Yancopoulos (Tarrytown, NY)

05.45 pm – 06.00 pm CLOSING SESSION & FAREWELL
Accepted Abstracts

All abstracts will be published in “Experimental Dermatology” (see printed abstract book in your meeting bag).

P001 First Evidence of Efficacy of an Orally Active RORγt Inhibitor in the Treatment of Patients with Moderate to Severe Plaque Psoriasis
Sally Palmer¹, Catherine Bryson¹, Gerard McGeehan¹, Deepak Lala¹, James Krueger², Richard Gregg³
¹Vitae Pharmaceuticals, Inc., Ft. Washington, PA, ²Rockefeller University, New York City, NY

P002 Characterization of the chloroquine-induced pruritus mouse model and its pharmacological modulation using an automated platform
Nuria Godessart¹, Carla Carcasona¹, Peter Eichhorn¹, Richard Roberts¹, Amadeu Gavalda¹, Gema Tarrason¹
¹Almirall R&D Center, Sant Feliu de Llobregat (Barcelona), Spain

P003 The 5-year experience of the use of ustekinumab for psoriasis
Theognosia Vergou¹, Christina Antoniou¹
¹University Clinic, A. Sygros Hospital, Athens, Greece

P004 Clinical and Histologic Patterns of Dermatologic Toxicity from Immune Checkpoint Blockade Therapy
Jonathan Curry¹, Michael Tetzlaff¹, Carlos Torres-Cabala¹, Omar Pacha, Auris Huen¹, Priyadharsini Nagarajan¹, Adi Diab¹, Carol Drucker¹, Ronald Rapini¹, Victor Prieto¹
¹MD Anderson Cancer Center, Houston, United States

P005 Successful treatment of granuloma faciale with the addition of etanercept to methotrexate therapy
Alexander Hicks¹, Nicole Colgrove², Kyle Owens³, Stuart Leicht³, George Youngberg⁴, M. Shah Shurbaji⁴
¹James H. Quillen College of Medicine, East Tennessee State University, Johnson City, United States, ²Department of Otolaryngology, University of Kentucky College of Medicine, Lexington, United States, ³Division of Dermatology, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, United States, ⁴Department of Pathology, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, United States

P006 Free fatty acids sensitize dermal cells to amplify TH1/TH17-immune responses
Diana Herbert¹, Kristin Stelzner¹, Yulia Popkova², Axel Lorz¹, Jürgen Schiller², Jan C. Simon¹, Anja Saalbach¹
P007 Semaphorin 4D contributes to inflammation of psoriasis by inducing cytokine production
Chen Zhang¹, Wei Li
¹Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Shaanxi, Xi’an, China

P008 Expression of dysfunctional apoptosis regulating proteins bcl-2 and p53 in psoriasis vulgaris
Debdeep Mitra¹, Biju Vasudevan²
¹Indian Air Force, Ranchi, India, ²Indian Army, Barackpore, India

P009 Interleukin-1 Gene Polymorphisms and their Relation with NFκB Expression and Histopathological Features in Psoriasis
Debdeep Mitra¹
¹Indian Air Force, Ranchi, India

P010 The pivotal role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III) - retrospective analyses of 74 patients
Christian Posch¹,², Babak Monshi¹, Tamara Quint¹, Igor Vujic¹,², Nikolaus Lilgenau¹, Klemens Rappersberger¹
¹The Rudolfstiftung Hospital, Vienna, Austria, ²Sigmund Freud University, Vienna, Austria

P011 Etanercept, adalimumab and ustekinumab in psoriasis vulgaris: detailed retrospective analysis of 209 treatment series in 134 patients in a single institution in Austria
Leo Richter², Igor Vujic¹,³, Martina Sanlorenzo², Alma Sesti², Christian Posch¹,³, Klemens Rappersberger¹
¹The Rudolfstiftung Hospital, Vienna, Austria, ²University of Turin, Turin, Italy, ³Sigmund Freud University, Vienna, Austria

P012 Improvement of DC vaccination strategies: Identification of a stable and migratory subset of IL-10 modulated dendritic cells.
Verena Raker¹, Fanny Kryczanowsky¹, Edith Graulich, Matthias Domogalla, Kerstin Steinbrink
¹University Medical Center, Dermatology, Mainz, Germany

P013 Location is everything: RNA-seq of distinct anatomic regions in psoriasis reveals distinct transcriptomic signatures for scalp, palmoplantar, and conventional plaque psoriasis
Richard Ahn¹, Kristina Lee¹, Kevin Lai¹, Keyon Taravati¹, Rasnik Singh¹,², Hsin-Wen Cheng¹, Zhi-Ming Huang¹, Derya Ucmak¹, Mio Nakamura¹, Tina Bhutani¹, Michael Rosenblum¹, Wilson Liao¹
¹University of California, San Francisco, San Francisco, United States, ²University of California, Los Angeles, Los Angeles, United States

P014 In situ mapping of innate lymphoid cells in healthy and inflamed human skin
Marie Charlotte Brueggen¹, Wolfgang Bauer¹, Baerbel Reininger¹, Eduard Clim³, Catalin Captarencu⁴, Georg Steiner⁵, Patrick M. Brunner¹, Barbara Meier², Lars French⁷, Georg Stingl¹
¹DIAID, Department of Dermatology, Medical University of Vienna, Vienna, Austria,
²Department Of Dermatology, University Hospital Zurich, Zurich, Switzerland,
³Department of Application Support and Image Processing, TissueGnostics, Iasi, Romania,
⁴Department of Product Development, TissueGnostics, Iasi, Romania,
⁵TissueGnostics GmbH, Vienna, Austria

P015 Transient neonatal zinc deficiency caused by a novel mutation in SLC30A2 gene
Mark Koh¹
¹KK Women’s & Children’s Hospital, Singapore, Singapore

P016 De novo missense variant in the KIT proto-oncogene in a child with piebaldism
Mark Koh¹
¹KK Women’s & Children’s Hospital, Singapore, Singapore

P017 IgE Sensitization Profiles differ between Adult Patients with Severe and Moderate Atopic Dermatitis
Catharina Johansson¹, Irene Mittermann², Gustav Wikberg³, Christian Lupinek², Lena Lundeberg³, Reto Cramer⁵, Rudolf Valenta⁴, Annika Scheynius¹
¹Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet and Sachs’ Children and Youth Hospital, Stockholm, Sweden, Stockholm, Sweden,
²Christian Doppler Laboratory for the Development of Allergen Chips, and Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria, Vienna, Austria,
³Department of Medicine Solna, Karolinska Institutet, and Dermatology and Venereology Unit, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden,
⁴Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria, Vienna, Austria,
⁵Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland, Davos, Switzerland
P018 Application of peanut protein on normal skin leads to tolerance whereas application on irritated skin leads to IgE sensitization
Vincent Dioszeghy1, Veronique Dhelft1, Melanie Ligouis1, Emilie Puteaux1, Pierre-Henri Benhamou1, Christophe Dupont9, Hugh Sampson3, Lucie Mondoulet1
1DBV Technologies, Montrouge, France, 2Necker Hospital, Paris Descartes University, Paris, France, 3DBV Technologies, New York City, USA

P019 Complementary in vitro activity of two compounds on non-histaminergic pathway of pruritus
Fabrice Lestienne1, Marguerite Leveque1, Helene Delga1, Marie-Francoise Aries1, Sandrine Bessou-Touya1, Nathalie Castex-Rizzi1
1Pierre Fabre Dermo Cosmetic, Toulouse, France

P020 Identification of an expression-based set of genes to predict the subset of patients with systemic sclerosis (SSc)
Pia Moinzadeh1, Peter Frommolt2, Marek Frantza3, Mohammad R Toliat3, Kerstin Becker3, Peter Nuernberg3, Svetlana I Nihtyanova4, Mona Ahrazoglu1, Doreen Belz1, Nicolas Hunzelmann1, David Abraham4, Voon H Ong4, Luc Mouthon5, Roger Hesselstrand6, Christopher P Denton6, Thomas Krieg1
1Department of Dermatology and Venerology, University of Cologne, Cologne, Germany, 2CECAD University of Cologne, Cologne, Germany, 3Cologne Center for Genomics, University of Cologne, Cologne, Germany, 4Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, Royal Free Hospital, London, London, United Kingdom, 5Université Paris Descartes, National Reference Centre for Scleroderma and Systemic Vasculitis (LM, LG), Cochin Hospital, Paris, Paris, France, 6Department of Rheumatology, Skåne University Hospital Lund, Lund, Sweden

P021 Association between atopic dermatitis and autoimmune disease in adults
Yuki M.F. Andersen1, Alexander Egeberg1, Gunnar Gislason2, Lone Skov1, Jacob Thyssen1
1Herlev and Gentofte Hospital, Dept. Of Dermatology And Allergy, Hellerup, Denmark, 2Herlev and Gentofte Hospital, Dept. of Cardiology, Hellerup, Denmark

P022 Prevalence of comorbidity and associated risk factors in adults with atopic dermatitis and psoriasis
Alexander Egeberg1, Yuki Andersen1, Gunnar Gislason2, Lone Skov1, Jacob Thyssen1
1Department Of Dermatology And Allergy, Herlev And Gentofte Hospital, Hellerup, Copenhagen, Denmark, Hellerup, Denmark, 2Department of Cardiology, Herlev And Gentofte Hospital, Hellerup, Copenhagen, Denmark, Hellerup, Denmark

P023 Local cyclic nucleotide repression inhibits Melanoma growth
Natascha Luther1, Toschka Bohn2, Edgar Schmitt2, Tobias Bopp2, Christian Becker1
1Department of Dermatology, University Medical Center Mainz, Mainz, Germany, 2Institute for Immunology, University Medical Center Mainz, Mainz, Germany
P024  Vδ1+T-cells are stress-sentinels in human skin and are implicated in alopecia areata pathogenesis
Yohei Uchida1,2, Jennifer Gherardini1, Majid Alam3, Aviad Keren4, Akiko Arakawa5, Alfredo Rossi6, Amos Gilhar4, Takuro Kanekura2, Marta Bertolini1,3, Ralf Paus1,7
1University of Münster, Münster, Germany, 2Kagoshima University, Kagoshima, Japan, 3Monasterium Laboratory, Münster, Germany, 4Technion-Israel Institute of Technology, Haifa, Israel, 5University of Munich, Munich, Germany, 6University „La Sapienza", Rome, Italy, 7University of Manchester, Manchester, United Kingdom

P025  Blistering of lesional skin is a sensitive and specific method to measure markers of disease activity in patients with vitiligo
Mehdi Rashighi1,2, James Strassner1, Jillian Richmond1, Maggi Ahmed Refat Ali1,3, John Harris1
1Department of Dermatology, University Of Massachusetts Medical School, Worcester, United States, 2Center for Research & Training in Skin Disease & Leprosy, Tehran University of Medical Sciences, Tehran, Iran, 3Department of Dermatology, Andrology and Venereology, Sohag University, Sohag, Egypt

P026  WITHDRAWN

P027  Increased Relapses and Complications in Pemphigus Patients Treated by the Same Physicians in a Public Safety Net Versus a Private University Healthcare System
Olivia Lai1, Michael Kasprzkiewicz2, Anna Betlachin3, Lingyun Ji3, Susan Groshen3, David Woodley1
1Eisenhower Medical Center, Rancho Mirage, United States, 2University of Lübeck, Lübeck, Germany, 3University of Southern California, Los Angeles, United States

P028  Improvement of Anti-inflammatory and Antibacterial Effects of Combined Crude Drug Extracts Including Barafu on Atopic dermatitis
Seoung Ki Jung1, Kangwon Kim2, Keun-Young Kim, Min Yu Song1, Woo-Tae Park1
1Bioresource Inc., Gwangju, South Korea, 2Young-Gwang Urologic Clinic, Gwangu, South Korea

P029  Topical Application of WOL074-019 Tripeptide Exhibits Anti-inflammatory Activity in Murine Model of Psoriasis
Carlo Sternemann2, Kerstin Vischedyk1, Meike Steinert2, Michael Soeberdt2, Ulrich Knie2, Christoph Abels2, Thomas A. Luger2, Karin Loser1
1Department of Dermatology, University of Muenster, Muenster, Germany, 2Dr. August Wolff GmbH & Co. KG – Arzneimittel, Bielefeld, Germany
P030 Interest of I-modulia, Aquaphilus dolomiae extract, in immune inflammatory response of atopic dermatitis pathology
Marie-Françoise Aries, Clémence Vaissière, Hélène Delga, Marguerite Lévêque, Thien N'Guyen, Sandrine Bessou-Touya, Nathalie Castex-Rizzi
1Pierre Fabre Dermo-Cosmétique, Toulouse, France

P031 Interest of I-modulia, an Aquaphilus dolomiae extract, in innate immune response of atopic dermatitis pathology
Marie-Françoise Aries, Hélène Hernandez-Pigeon1, Clémence Vaissière, Antony Caruana, Thien N’Guyen, Sandrine Bessou-Touya, Nathalie Castex-Rizzi
1Pierre Fabre Dermo-Cosmétique, Toulouse, France

P032 MicroRNA-146a suppresses IL-17-mediated skin inflammation and is genetically associated with psoriasis
Ankit Srivastava1, Pernilla Nikamo1, Warangkana Lohcharoenkal1, Dongqing Li1, Florian Meisgen1, Ning Xu Landén1, Mona Stahle1, Andor Pivarcsi1, Eniko Sonkoly1
1Karolinska Institutet, Stockholm, Sweden

P033 KPI-150 a potent inhibitor of Kv1.3 potassium channels demonstrates preclinical proof-of-concept efficacy against atopic dermatitis when applied topically
Emma Guttman-Yassky1, Kurt Lustig2, Chelsea Olsen3, Shawn ladonato2, Eric Tarcha2
1The Department of Dermatology and the Immunology Institute, Icahn School of Medicine at the Mount Sinai Medical Center, New York, United States, 2Kineta Inc, Seattle, United States, 3KPI Therapeutics Inc, Seattle, United States

P034 A 0.05 % hypochlorous acid gel displays anti-itch and anti-inflammatory properties in a chronic mouse model of atopic dermatitis - possible direct effect on neurons
Tomoki Fukuyama1, Britta C. Martel1, Wolfgang Bäumer1
1Department of Molecular Biomedical Sciences, College of Veterinary Medicine, NC State University, Raleigh, United States

P035 UV-induced inhibition of adipokine production in subcutaneous fat aggravates dermal matrix degradation in human skin
Eun Ju Kim1,2,3, Yeon Kyung Kim1,2,3, Min Kyoung Kim1,2,3, Sungsoo Kim1,2,3, Jin Young Kim1,2,3, Dong Hun Lee1,2,3, Jin Ho Chung1,2,3
1Department of Dermatology, Seoul National University College of Medicine, Seoul, South Korea, 2Laboratory of Cutaneous Aging Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea, 3Institute of Human-Environment Interface Biology, Seoul National University, Seoul, South Korea
P036  Hidradenitis Suppurativa Is Associated with Familial Mediterranean Fever - A Population-Based Study
Emmilia Hodak1,2, Lihi Atzmony1, Lev Pavlovsky1, Doron Comaneshter3, Arnon Cohen3,4
1Department of Dermatology, Rabin Medical Center – Beilinson Hospital, Petach Tikva, Israel,
2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 3Department of Quality
Measurements and Research, Chief Physician’s Office, Clalit Health Services, Tel Aviv, Israel,
4Sial Research Center for Family Medicine and Primary Care, Division of Community Health,
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel

P037  Investigation of the effect of tofacitinib on keratinocytes
Ankit Srivastava1, Mona Ståhle1,2, Andor Pivarcsi1, Enikő Sonkoly1,2
1Dermatology and Venerology Unit, Department of Medicine, Karolinska Institutet,
Stockholm, Sweden, 2Unit of Dermatology, Karolinska University Hospital, Stockholm,
Sweden

P038  Role of Fucosyltransferase 8 in Pathogenesis of Epidermal Proliferation/ Differentiation and Psoriasis Development
Yungling Lee1, Liang-Chun Liou1, Huai-Ting Huang1, Yi-Hsuan Wang1
1Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan

P039  Th2 cells and basophils expressing IL-4 together with ILC2 expressing IL-13 infiltrate skin lesions of patients with atopic dermatitis but not psoriasis
Shunya Mashiko1, Robert Bissonnette2, Marika Sarfati1
1CRCHUM, Montreal, Canada, 2Innovaderm, Montreal, Canada

P040  Expression level of microRNA in the peripheral blood and tissue of untreated and narrowband ultraviolet B (NBUVB) treated active generalized vitiligo
Anita Singh Parihar1, Vinod Kumar Sharma1, Manoj Kumar Tembhre2, Somesh Gupta1, Sonam
Singh1
1All India Institute Of Medical Sciences (AIIMS), New Delhi, Delhi, India, 2Feinstein Institute
of Medical Research, Manhasset, United States

P041  CD109 is a key regulator of the IL-23/IL-17 immune axis in the skin
Giustino Carnevale, Ghislaine Fontes, Irah King1
1Mcgill University, Montreal, Canada

P042  Identification of parameters that could predict time to return of symptoms after stopping omalizumab treatment: exploratory analysis of Phase III data from patients with chronic idiopathic/spontaneous urticaria (CIU/CSU)
Marta Ferrer1, Ana Giménez-Arnau2, Diego Saldana3, Nico Janssens3, Maria-Magdalena Balp3, Sam Khalii3, Valery Risson3
P043 Omalizumab effectively reduces angioedema episodes in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU)
Petra Staubach1, Martin Metz2, Nadine Chapman-Rothe3, Christian Sieder3, Matthias Braeutigam3, Janice Canvin4, Marcus Maurer2
1Hautklinik und Poliklinik, Johannes Gutenberg-Universität Mainz, Mainz, Germany, 2Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, Berlin, Germany, 3Novartis Pharma GmbH, Nürnberg, Germany, 4Novartis Pharma AG, Basel, Switzerland

P044 Omalizumab normalizes gene expression in lesional skin of patients with chronic idiopathic/spontaneous urticaria: results from a randomized, double-blind, placebo-controlled study
Martin Metz1, Rebecca Torene2, Martin Letzkus3, Nicole Hartmann3, Petra Staubach4, Andrea Bauer2, Randolf Brehler5, Janine Gercke1, Joanna Ashton-Chess3, Philip Jarvis3, Veit J Erpenbeck3, Marcus Maurer1
1Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, Berlin, Germany, 2Novartis Pharmaceuticals Corporation, Cambridge, United States, 3Novartis Pharma AG, Basel, Switzerland, 4Department of Dermatology, University Medical Center Mainz, Mainz, Germany, 5Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany

P045 Antibiotic exposure limited to early life causes intestinal dysbiosis and exacerbation of skin and lung pathology in murine experimental systemic sclerosis
Heena Mehta1, Philippe-Olivier Goulet1, Shunya Mashiko1, Jade Desjardins1, Gemma Perez2, Martial Koenig2, Jean-Luc Senecal2, Marco Constanze3, Manuela Santos3, Marika Sarfati1
1Immunoregulation Laboratory, CRCHUM, Montreal, Canada, 2Laboratory for Research in Autoimmunity, CRCHUM, Montreal, Canada, 3Nutrition and Microbiome Laboratory, CRCHUM, Montreal, Canada

P046 CD8+ polycytotoxic T cells are defined by natural killer cell receptors and exhibit antimicrobial activity against intracellular bacteria
Robert Modlin1, Samuel Balin1, David Weiss1, Joshua Hakimian1, Matteo Pellegrini2, Maria Teresa Ochoa3, Thomas Rea4, Steffen Stenger4, Barry Bloom5
1UCLA, Division of Dermatology, Department of Medicine, Los Angeles, United States, 2UCLA, Department of Microbiology, Immunology and Molecular Genetics, Los Angeles, United States, 3USC School of Medicine, Department of Dermatology, Los Angeles, United States
P047  **Inhibition by oral administration of Lactobacillus pentosus KF340 of atopic dermatitis-like symptoms induced by house dust mite in mouse: Control of splenic B10 cell differentiation by lactic acid bacteria**

Min-jung Bae1, Hyun-Keun Kim2, Seonung Lim2, Sunyoung Kim1,2,3

1 Institutes of Entrepreneurial BioConvergence, Seoul National University, Seoul, South Korea, 2 Laboratory of Virology, School of Biological Sciences, Seoul National University, Seoul, South Korea, 3 ViroMed Co., Ltd., Seoul, South Korea

P048  **Streptococcus pyogenes activation of circulating CLA+ T cells in guttate and chronic plaque psoriasis patients: IL-9 production dependence on time of flare, PASI, ASO levels, and relationship with IL-17 response**

Ester Ruiz-Romeu1, Marta Ferran2, Marc Sagristà3, Pablo García4, Ramon M Pujol5, Luis F Santamaria-Babí4

1 Translational Immunology. University of Barcelona, Barcelona, Spain, 2 Department of Dermatology. Hospital del Mar, Barcelona, Spain, 3 Hospital Sant Jaume de Calella, Barcelona, Spain, 4 Macrophage Biology. University of Barcelona, Barcelona, Spain

P049  **Targeted therapy in auto-inflammatory diseases: A successful case of aseptic abscess syndrome**

Andreas Benedikt Weins1, Tilo Biedermann1, Anca Sindrilaru2, Diana Crisan2, Hehl2, Johannes Martin Weiss2, Karin Scharffetter-Kochanek2, Kilian Eyerich1

1 Department Of Dermatology and Allergy, Biederstein Campus. Technical University of Munich (TUM), München, Germany, 2 Department Of Dermatology and Allergy, Ulm, Germany

P050  **TNIP1 loss sensitizes post-receptor signaling following exposure to TLR agonists**

Swetha Rudraiah1, Rambon Shamilov1, Brian Aneskievich1

1 University of Connecticut, Storrs, United States

P051  **Induction of remission and cytokine levels in pemphigus after selective plasma exchange therapy**

Hilayda Karakök Güngör1, Seçil Saral1, Mustafa Gündoğdu1, Cengizhan Erdem1, Nihal Kundakçı1

1 Ankara University Medical Faculty, Ankara, Turkey

P052  **Proseek Multiplex: A precision proteomics solution for targeted human protein biomarker discovery**

Iad Grundberg1

1 Olink Proteomics Inc., 201 Dexter Avenue, Watertown, MA, United States
P053 Interleukin-13 in Cutaneous T-cell Lymphoma - The Missing Link Between Inflammation and Malignancy
Larisa Geskin1, Sara Viragova3, Donna B. Stolz4, Anna Lokshin5,6,8, Oleg Akilov2, Patrizia Fuschiotti5,6,7
1Department of Dermatology, Columbia University, New York, United States, 2Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, United States, 3Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, United States, 4Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States, 5Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, United States, 6Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, United States, 7University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, United States

P054 Isolation of Anti-Psoriatic Activities from Actinidia arguta: Suppression of Imiquimod-Induced Psoriasis by Modulating Neutrophil-Infiltration to Skin
Hyun-keun Kim1, Seonung Lim1, Min-Jung Bae2, Sunyoung Kim1,2,3
1Laboratory of Virology, School of Biological Sciences, Seoul National University, Seoul, Korea, 2Institutes of Entrepreneurial BioConvergence, Seoul National University, Seoul, Korea, 3ViroMed Co., Ltd, Seoul, Korea

P055 GILZ overexpression increases psoriasis-like features and involves skin TGF-β1 activation in an Imiquimod-induced psoriasis mouse model
Elena Carceller1, Marlies Ballegeer2,3, Carlo Riccardi4, Stefano Bruscoli4, Tino Hochepied2,3, Claude Libert2,3, Paloma Pérez1
1Instituto de Biomedicina de Valencia-Consejo Superior de Investigaciones Científicas (IBV-CSIC), Valencia, Spain, 2Inflammation Research Center, VIB, Ghent, Belgium, 3Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium, 4Department of Medicine, University of Perugia Medical School, Perugia, Italy

P056 Langerhans cells can infiltrate primary cutaneous melanomas and display a tolerogenic phenotype
Judith Seidel1, Atsushi Otsuka1, Kenji Kabashima1
1Kyoto University, Kyoto, Japan

P057 WITHDRAWN

P058 Immunological analysis of metastatic melanoma patients treated with
nivolumab; is Th9 cell subset a possible biomarker of treatment efficacy?
Yumi Nonomura1, Atsushi Otsuka1, Chisa Nakashima1, Judith Seidel1, Kenji Kabashima1
1Kyoto University Graduate School Of Medicine, Kyoto, Japan

P059 Autoimmune comorbidities among 10 psoriatic patients
Anna-Maija Matela1, Hellevi Ruokonen2, Jaana Hagström2, Liisa Väkevå2
1Department of Oral and Maxillofacial Diseases, Head and Neck Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

P060 Novel Promotion of Skin Innate Lymphoid Cell Activity by CD200R1
Holly Linley1, Karishma Mohamed1, Tracy Hussell1, Amy Saunders1
1University Of Manchester, Manchester, United Kingdom

P061 IL-23 pathway inhibition by risankizumab differentially modulates the molecular and histopathological profile in psoriatic skin compared with ustekinumab
Sudha Visvanathan1, Patrick Baum2, Richard Vinisko2, Ramona Schmid2, Mary Flack1, Judilyn Fuentes-Duculan3, Jay S. Fine1, Steven Padula4, James Krueger3
1Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, USA, 2Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, 3Rockefeller University, New York, USA, 4Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

P062 Arginase1/iNOS imbalance mediates cutaneous contact hypersensitivity responses
Jutamas Suwanpradid1, Michael Shih1, MD Bin Yang1, Anastasiya Birukova2, Loretta Que2, Robert Tighe2, Amanda S MacLeod1,3
1Dermatology, Duke University, Durham, United States, 2Medicine, Duke University, Durham, United States, 3Immunology, Duke University, Durham, United States

P063 Secukinumab, a new anti-IL17A biologic therapy, induces rapid and durable clinical, histological, and molecular resolution of psoriasis plaques over 1 year of administration
James G Krueger2, Keith Wharton Jr2, Thomas Schlitt3, Rebecca Torene2, Xiaoyu Jiang4, Claire Q Wang1, Judilyn Fuentes-Duculan1, Mayte Suárez-Fariñas1, Nicole Hartmann4, Thomas Peters3, Marc Sultan3, Irina Koroleva2, Rainer Hillenbrand3, Martin Letzkus3, Xiaojing Yü5, Yue Li6, Anke Hasselberg6, Brian Flannery6, Wolfgang Hueber3
1Laboratory of Investigative Dermatology, The Rockefeller University, New York, United States, 2Novartis Institutes for Biomedical Research, Cambridge, United States, 3Novartis Pharma AG, Basel, Switzerland, 4Merrimack, Cambridge, United States, 5Novartis Institutes
P064 Periodontitis in Oral Pemphigus and Pemphigoid: A Systematic Review of Published Studies
Isabella Jascholt1, Olivia Lai2, Detlef Zillikens1,3, Michael Kasperkiewicz1,3
1 Department of Dermatology, University of Lübeck, Lübeck, Germany, 2 Eisenhower Medical Center, Rancho Mirage, USA, 3 Lübeck Institute of Experimental Dermatology, University of Lübeck, Germany

P065 Gender differences in central processing and perception of itch: “same same but different” - Preliminary results of a study using functional MRI
Simon Mueller1, Peter Itin1, Stephan Borgwardt1, Christoph Stippich1, Julia Reinhardt3
1 Department Of Dermatology, University Hospital Basel, Basel, Switzerland, 3 Diagnostic and Interventional Neuroradiology, University Hospital Basel, Basel, Switzerland

P066 Characterization of multiple B cell subsets in peripheral blood of psoriasis patients identifies a correlation of plasma and regulatory B cells with disease severity
Jenny Thomas1, Natalie Garzorz-Stark2, Lena Küpper2, Linda Krause3, Nikola Müller2, Tilo Biedermann2, Fabian Theis3, Carsten Schmidt-Weber1, Kilian Eyerich2, Stefanie Eyerich1
1 ZAUM – Center for Allergy and Environment, Member of the German Center for Lung Research (DZL), Technical University of Munich and Helmholtz Center Munich, Munich, Germany, 2 Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany, 3 Institute of Computational Biology, Helmholtz Center Munich, Munich, Germany

P067 A longitudinal study of the association between preschool eczema or filaggrin mutations and IgE sensitization up to 16 years of age
Emma Kristin Johansson1,2, Natalia Ballardini3,4,5, Anna Bergström3, Inger Kull5,6, Tomas Lind7, Marianne van Hage8, Magnus Wickman3,5, Carl-Fredrik Wahlgren1,9
1 Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet, SE-171 77 Stockholm, Sweden, 2 Dermatological and Venereal Clinic, Södersjukhuset, Stockholm, Sweden, 3 Sachs’ Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, 4 St John’s Institute of Dermatology, King’s College London, London, U.K., 5 Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 6 Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, 7 Department of Occupational and Environmental Medicine, Stockholm County Council, Stockholm, Sweden; Unit of Environmental Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 8 Immunology and Allergy Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 9 Department of Dermatology, Karolinska University Hospital Solna, Stockholm, Sweden
P068 High circulating miR-146a plasma levels found in obese patients with moderate to severe plaque psoriasis can be reduced by anti-TNFs agents
Juan Ruano1,2, Pedro Jesús Carmona-Fernández1, Macarena Aguilar-Luque1, Jesús Gay-Mimbrera1, Marcelino González-Padilla1,2, Francisco Gómez-García1,2, Jose-Luis Sanz-Cabanillas1,2, Beatriz Isla-Tejera1,3, Antonio Vélez García-Nieto1,2
1Inflammatory Immune-mediated Skin Disease research group, IMIBIC, Córdoba, Spain, 2Department of Dermatology, Reina Sofia University Hospital, Córdoba, Spain, 3Department of Pharmacy, Reina Sofia University Hospital, Córdoba, Spain

P069 Crisaborole Demonstrates Improvement in Quality of Life in Patients With Mild to Moderate Atopic Dermatitis
Eric Simpson1, Amy Paller2, Mark Boguniewicz3,4, Lawrence Eichenfield5,6, Steven Feldman7, Jonathan Silverberg2, Sarah Chamlin8, Lee Zane9
1Oregon Health and Science University, Portland, USA, 2Northwestern University, Feinberg School of Medicine, Chicago, USA, 3National Jewish Health, Denver, USA, 4University of Colorado School of Medicine, Denver, USA, 5Rady Children's Hospital, San Diego, USA, 6University of California, San Diego, La Jolla, USA, 7Wake Forest School of Medicine, Winston-Salem, USA, 8Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Feinberg School of Medicine, Chicago, USA, 9Anacor Pharmaceuticals, Inc., Palo Alto, USA

P070 E-cadherin and p120 ctn expression is lost in hidradenitis suppurativa lesions
Amanda Nelson1, Zhaoyuan Cong1, Doug Stairs1, Catherine Chung1, William Danby2
1Penn State College Of Medicine, Hershey, United States, 2Geisel School of Medicine at Dartmouth, Hanover, USA

P071 Long-Term Safety of Crisaborole, A Novel, Nonsteroidal, Anti-Inflammatory Phosphodiesterase 4 Inhibitor, in Children and Adults With Mild to Moderate Atopic Dermatitis
Lawrence Eichenfield1,2, Robert Call9, Douglass Forsha4, Joseph Fowler Jr5, Adelaide Hebert6, Mary Spellman7, Linda Stein Gold8, Merrie Van Syoc7, Lee Zane7, Eduardo Tschen9
1University of California, San Diego, San Diego, USA, 2Rady Children’s Hospital, San Diego, USA, 3Clinical Research Partners, Richmond, USA, 4Jordan Valley Dermatology & Research Center, West Jordan, USA, 5Dermatology Specialists Research, LLC, Louisville, USA, 6University of Texas Health Science Center, Houston, USA, 7Anacor Pharmaceuticals, Inc., Palo Alto, USA, 8Henry Ford Health System, Detroit, USA, 9Academic Dermatology Associates, Albuquerque, USA

P072 Dysregulated expression of TSP-1 and its receptor CD47 in Psoriasis
Hortensia De La Fuente1, Mar Llamas Velasco2, Danay Cibrian1, Francisco Sánchez Madrid1, Esteban Daudén2
P073  ATx201: A novel antibiotic for treatment of skin infections caused by multidrug resistant bacteria
Morten Sommer

P074  A distinct molecular signature of interface dermatitis as determined by gene expression analysis combined with disease independent histological phenotyping

P075  The role of Candida albicans in the pathogenesis of psoriasis
Saeko Nakajima, Oliver Harrison, Dean Merrill, Jonathan Linehan, Yasmine Belkaid

P076  Altered lycopene isomer ratio and reduced carotenoid and retinoid concentrations in plasma of atopic dermatitis patients
Renata Lucas, Daniel Töröcsik, Gordon Lowe, Ralph Rühl

P077  Towards the clonotype analysis of alopecia areata-specific, intralesional human CD8+ T-lymphocytes
Marta Bertolini, Sabrina Altendorf, Yohei Uchida, Quingquing Zhou, Alfredo Rossi, Klaus Dornmair, Ralf Paus

P078  The Role of Dermoscopy in the Evaluation of Inflammatory Dermatoses
Elizabeth Seiverling, Lauren Cook, Courtney Hanna, Galen Foulke

P079  Efficacy of an emollient containing Rhealba oat plantlets on idiopathic
pruritus among elderly French outpatients.
Jennifer Theunis1, Ana Beatris Rossi1, Nathalie Castex Rizzi1, Valerie Mengeaud1
1Pierre Fabre Dermocosmetique, Toulouse, France

P080 EVALUATION OF SERUM URIC ACID AMONG PATIENTS WITH PSORIASIS IN DEVELOPING COUNTRY
Shambhu Dutta Joshi1, Lokendra Limbu2
1Bhaktapur Hospital, Bhaktapur, Nepal, 2Shahid Memorial Hospital, Kathmandu, Nepal

P081 Occupational Eczema and How the community responses in developing country
Rajan Prasad Bhandari1
1Community Health And Environmental Society Nepal, Kathmandu, Nepal

P082 Epicutaneous treatment with a p38 MAPK activator is sufficient to induce the IL-17-dependent psoriasis-like dermatitis in a new animal model
Teruki Dainichi1, Kenji Sakurai1, Reiko Matsumoto2, Yuri Nakano1, Kenji Kabashima1
1Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan

P083 CD34+ skin resident precursor cells may contribute to maintain tissue resident macrophages in human skin and are stimulated by substance P and IFNy
Jennifer Gherardini1, Youhei Uchida2, Jérémy Chéret3, Majid Alam3, Marta Bertolini1, Ralf Paus4
1Münster University, Münster, Germany, 2Kagoshima University, Kagoshima, Japan, 3Monasterium Laboratory, Münster, Germany, 4Manchester University, Manchester, United Kingdom

P084 Contribution of IgE Autoantibodies to the Pathogenesis of Bullous Pemphigoid
Patricia Freire1, Peter Heil1, Georg Stingl1
1Department of Dermatology – Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria

P085 Induction of alternative proinflammatory cytokines accounts for sustained psoriasiform skin inflammation in IL-17C+IL-6KO mice
Yi Fritz2, Philip Klenotic1, William Swindell1, ZhiQiang Yin2, Sarah Groft1, Li Zhang1, Jamie Baliwag2, Maya Camhi1, Doina Diaconu1, Andrew Young3, Alexander Foster2, Andrew Johnston4, Johann Gudjonsson2, Thomas McCormick1, Nicole Ward1
1Case Western Reserve University, Cleveland, United States, 2University of Michigan, Ann Arbor, United States

P086 Imiquimod has strain-dependent effects in mice and does not uniquely model human psoriasis
Johann Gudjonsson¹, William Swindell¹, Kellie Michaels², Andrew Sutter², Doina Diaconu², Yi Fritz², Xianying Xing¹, Mrinal Sarkar¹, Yun Liang¹, Alex Tsoi¹, Nicole Ward²
¹University of Michigan, Ann Arbor, United States, ²Case Western Reserve University, Cleveland, United States

P087 New novel chimeric immunoreceptors for pemphigus vulgaris (PV) therapy
Christoph T. Ellebrecht¹, Vijay G. Bhoj¹, Arben Nace¹, Michael J Cho¹, Xuming Mao¹, John T. Seykora¹, George Cotsarelis³, Michael C. Milone¹, Aimee S. Payne¹
¹University Of Pennsylvania, Philadelphia, United States

P088 Biosimilar Infliximab - Is intracellular signaling the same after switching?
Anders Krogh Aarebrot¹, Silje Michelsen Solberg¹,², Richard Davies³, Staff Engineer Marianne Eidsheim¹, Kjerstin Jakobsen¹, Lucius Bader³, Sonia Gavasso³, Yenan Bryceson¹,², Tim D. Holmes¹,², Lene Frøyen Sandvik¹,², Roland Jonsson¹,³, Silke Appel¹
¹Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ²Department of Dermatology, Haukeland University Hospital, Bergen, Norway, ³Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ⁴Centre for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden, ⁵Department of Clinical Medicine, University of Bergen, Bergen, Norway

P089 Calcipotriol enhances cathelicidin expression and improves bacterial defense and wound closure in epidermolysis bullosa
Christina Gruber¹, Josefina Pinon Hofbauer¹, Birgit Tockner¹, Cornelia Scharler², Clemens Hüttner¹, Andrea Trost¹, Dirk Strunk², Johann Wolfgang Bauer², Julia Reichelt¹, Roland Lang⁴
¹EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital of the Paracelsus Medical University (PMU), Salzburg, Austria, ²Experimental & Clinical Cell Therapy Institute, Core Facility for Flow Cytometry, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCITReCS), PMU Salzburg, Salzburg, Austria, ³University Clinic of Ophthalmology and Optometry, Research program for Ophthalmology and Glaucoma Research, Paracelsus Medical University Salzburg, Salzburg, Austria, ⁴Department of Dermatology, University Hospital Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria

P090 Association between Patient-Perceived Effectiveness of Immunosuppressants/Phototherapy and Patient-Reported Outcomes among Adults with Atopic Dermatitis: Data From a US Cross-Sectional Study (AWARE)
Emma Guttman-Yassky¹, Eric Simpson², David Margolis³, Steven Feldman⁴, Abrar Qureshi⁵, Wenhui Wei⁶, Laurent Eckert⁷, Renée Arnold⁸, Tiffany Yu⁹, Tessa Hata⁹, Vera Mastey¹⁰, Abhijit Gadkari¹⁰, Jingdong Chao¹⁰
¹Department of Dermatology and the Immunology Institute, Icahn School of Medicine
Epigenetic modifications in skin-homing CD4+CLA+ T-cells of atopic dermatitis patients relate to mRNA expression changes in high mobility group proteins

Shintaro Katayama3, Sören Bruhn2, Annika Scheynius1, Lena Lundeberg5, Juha Kere34, Anna Andersson2, Cilla Söderhäll3, Nancy Yiu-Lin Yu3, Dario Greco2, Kaarel Krjutskov345, Gustav Wikberg6, Elisabet Einarsdottir34, Nathalie Acevedo1

1Department of Clinical Science and Education, Karolinska Institutet, and Sachs’ Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, 2Department of Medicine Solna, Translational Immunology Unit, Karolinska Institutet, Stockholm, Sweden, 3Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden, 4Molecular Neurology Research Program, University of Helsinki, and Folkhålsan Institute of Genetics, Helsinki, Finland, 5Competence Centre on Health Technologies, Tartu, Estonia, 6Dermatology and Venerology Unit, Karolinska University Hospital, Stockholm, Sweden, 7Institute of Biotechnology, University of Helsinki, Helsinki, Finland

CD49a expression reveal functional dichotomy in cytokine production and cytotoxic capacity in tissue resident T cells in healthy, psoriasis and vitiligo affected skin.

Stanley Cheuk1, Heinrich Schlums1, Irene Gallais Sérézal1, Samuel Chiang, Marcus Ehrström1, Mona Ståhle1, Yenan Bryceson1, Liv Eidsmo1

1Karolinska Institutet, Stockholm, Sweden

Efficacy, safety and pharmacodynamics of a high-affinity anti-IgE antibody in patients with moderate to severe atopic dermatitis: a randomized, double-blind, placebo-controlled, proof-of-concept study

Christine Bangert1, Christian Loesche2, Julie Jones2, Doris Weiss1, Thomas Bieber3, Georg Stingl1

1Department of Dermatology, DIAID, Medical University, Vienna, Austria, 2Novartis Institutes of Biomedical Research, Basel, Switzerland, 3Department of Dermatology, University Hospital of Bonn, Bonn, Germany

β-defensin-2 (BD-2) responds to a single dose of anti-IL-17A secukinumab in different skin layers of psoriatic patients within days

P094
P095 Inflammatory skin conditions in patients under anticancer therapies: observations from an oncodermatology clinic.
Azrael Freites-Martinez, Dulce Barrios, Mario Lacouture

1 Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, United States

P096 Efficacy and Safety of Ixekizumab in Patients Previously Treated with Etanercept
Andrew Blauvelt, Kim Papp, Christopher E. M. Griffiths, Lotus Mallbris, Yves Dutronic, Dapo Ilo, Lu Zhang, Luis Puig

1 Oregon Medical Research Center, Portland, USA, 2K. Papp Clinical Research and Probity Medical Research, Waterloo, Canada, 3 Dermatology Centre, Salford Royal Hospital, Manchester, United Kingdom, 4 Eli Lilly and Company, Indianapolis, USA, 5 Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain

P097 Efficacy and Safety of Ixekizumab over Four Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis
Kenneth Gordon, Craig Leonardi, Andrew Blauvelt, Claus Zachariae, Gregory Cameron, Missy McKean-Matthews, Terri Ridenour, Mark Lebwohl

1 Northwestern University Feinberg School of Medicine, Chicago, USA, 2 Saint Louis University School of Medicine, St. Louis, USA, 3 Oregon Medical Research Center, Portland, USA, 4 University Hospital of Copenhagen Gentofte, Hellerup, Denmark, 5 Eli Lilly and Company, Indianapolis, USA, 6 Icahn School of Medicine at Mount Sinai, New York, USA

P098 Time Course of Ixekizumab Drug Levels and the Relationship at Week 60 to Efficacy in Patients with Moderate-to-Severe Plaque Psoriasis (UNCOVER-3)
Kristian Reich, Siak Leng Choi, Kimberley Jackson, Lotus Mallbris, Andrew Blauvelt

1 Dermatologikum Hamburg, Hamburg, Germany, 2 Lilly-NUS Centre for Clinical Pharmacology, Singapore, Singapore, 3 Eli Lilly and Company, Global PKPD and Pharmacometrics, Windlesham, UK, 4 Eli Lilly and Company, Indianapolis, USA, 5 Oregon Medical Research Center, Portland, OR

P099 Attenuated dynamic of IMQ-induced psoriasis in inflammasomes KO mice models
P100 The inpatient burden of pediatric autoimmune blistering disease in the United States
Ziyou Ren1, Derek Hsu, Nanette Silverberg2, Jonathan Silverberg1
1Northwestern University Feinberg School Of Medicine, Chicago, United States, 2Mount Sinai Icahn School of Medicine, New York, United States

P101 Psoriasis and psoriatic arthritis are associated with osteoporosis and pathological fractures
Parul Kathuria1, Kenneth Gordon1, Jonathan Silverberg1
1Northwestern University Feinberg School Of Medicine, Chicago, United States

P102 Epidemiology of Erythema Multiforme Major, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in US children
Joaquin Brieva1, Nanette Silverberg2, Amy Paller1, Jonathan Silverberg1
1Northwestern University Feinberg School Of Medicine, Chicago, United States, 2Mount Sinai Icahn School of Medicine, New York, United States

P103 Eczema, atopic dermatitis or atopic eczema? An analysis of lay terms by global search engine trends
Steve Xu1, Jacob Thyssen2, Amy Paller1, Jonathan Silverberg1
1Northwestern University Feinberg School Of Medicine, Chicago, United States, 2Gentofte University Hospital, Hellerup, Denmark

P104 The Endocannabinoid System: An Untapped Source for Dermatologic Therapies
Jonathan Bonchak1, Brian Pollack2, Sarah Chisolm3
1Emory Dermatology, Atlanta, United States, 2Emory Dermatology, Atlanta, United States, 3Emory Dermatology, Atlanta, United States

P105 Altered inflammasome and integrin profiles in circulating classical (CD14+CD16neg) monocytes and adherent monocyte pairs in psoriasis
Jackelyn Golden1, Brian Richardson1, Thomas McCormick1, Mark Cameron1, Kevin Cooper1
1Case Western Reserve University, Cleveland, United States

P106 Epidemiological study of pediatric atopic dermatitis severity
Jonathan Silverberg1, Amy Paller1
1Northwestern University Feinberg School Of Medicine, Chicago, United States

P107 Altered composition of epidermal lipids correlates with Staphylococcus aureus colonization status in adult Atopic Dermatitis subjects
P108 Corticosteroid application prior to nickel exposure prevents contact dermatitis in sensitized individuals
Paulina Piesik1, Dr. Gillian de Gannes2, Dr. Jan Dutz1,2
1 Child and Family Research Institute, Vancouver, Canada, 2Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada

P109 Treatment of Dermatoses associated with hyperhomocysteinemia
Peter Aronson1
1 Wayne State University, John D. Dingell VAMC, Dearborn and Detroit, United States

P110 Initial validation of the Burden of Disease in Atopic Eczema (BODE) instrument, a quality of life measure for adult atopic dermatitis
Annie Wang1, Rachel Dunlap1, Marwa Darwish1, Eric Simpson2, Jon Hanifin2, Abrar Qureshi1, Aaron Drucker1
1Department Of Dermatology, Brown University, Providence, United States, 2Department of Dermatology, Oregon Health and Science University, Portland, United States

P111 The epithelial DLX3-dependent transcriptome regulates skin immune homeostasis
Shreya Bhattacharya1, Jin-Chul Kim1, Gaku Nakato2, Youichi Ogawa2, Meghan Kellet1, Mark C. Udey3, Maria I. Morasso1
1Laboratory of Skin Biology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, United States, 2Dermatology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, United States

P112 Alterations in B-cell subsets in early pediatric atopic dermatitis
Tali Czarnowicki1,2, Hitokazu Esaki1,2, Juana Gonzalez1, Sreya Talasila3, Isabel Haugh3, James Krueger1, Emma Guttman-Yassky1,2, Amy Paller3
1Rockefeller University, New York, United States, 2Icahn School of Medicine at Mount Sinai, New York, United States, 3Northwestern University, IL, United States

P113 Early onset pediatric atopic dermatitis is Th2, but also Th17 polarized in skin
Tali Czarnowicki1,2, Hitokazu Esaki1,2, Patrick Brunner1, Giselle Rodriguez3, Supriya Immaneni3, Yael Renert-Yuval2, Mayte Suárez-Fariñas2, James Krueger1, Amy Paller3, Emma Guttman-Yassky1,2
1Rockefeller University, New York, United States, 2Icahn School of Medicine at Mount Sinai, New York, United States, 3Northwestern University, IL, United States
P114 Dietary modifications in atopic dermatitis: patient reported outcomes
1University of California San Francisco, San Francisco, United States

P115 Histopathological Characterization of Trichrome Vitiligo
Xiaoxiao Li1, Juana Garza Chapa1, Amit Pandya1
1UT Southwestern, Dallas, United States

P116 Non-steroid like phytochemical, shikonin, as a candidate drug lead for promoting inflammation-resolution in skin diseases
Ning-sun Yang1, Mitapalli S Pradeep1, Shu Yi Yin1
1ABRC, Academia Sinica, Taipei, Taiwan. Taipei, Taiwan

P117 Withdrawn

P118 Modulation of the cutaneous microbiome through Dead Sea Climatotherapy
Michael Brandwein1,2, Garold Fuchs3,4, Avigail Israel2, Dr. Marco Harari5, Zvi Bentwich2, Noam Shental3, Doron Steinberg1, Shiri Meshner2
1Hebrew University Of Jerusalem, Jerusalem, Israel, 2The Dead Sea and Arava Science Center, Ein Gedi, Israel, 3The Open University of Israel, Raanana, Israel, 4Weizmann Institute of Science, Rehovot, Israel, 5DMZ-MOR Rehabilitation Clinic, Ein Bokek, Israel

P119 Autoimmune blistering diseases associated with parotid mucoepidermoid carcinoma: a report of two cases
Lauren Albers1, Dr. Ron Feldman1
1Emory University, Atlanta, United States

P120 Integration of Transcriptome-wide Clinical Acne, Atopic Dermatitis, and Psoriasis Data for Therapeutic Target Discovery and Indication Expansion
Johannes M Freudenberg1, Deepak K Rajpal1
1Target Sciences Computational Biology, GlaxoSmithKline, Glaxosmithkline, King Of Prussia, United States

P121 Bacterial biofilm and the S. aureus derived protease, staphopain, are present on the skin surface of patients with atopic dermatitis
Andreas Sonesson1, Kornikowa Przybyszewska2, Matthias Mörgelin3, Sven Kjellström4, Julia Davies5, Jan Potempa5, Artur Schmidtchen1
1Lund University, Clinical Sciences, Division of Dermatology and Venereology, Lund, Sweden, 2Center for Infection and Immunity, School of Medicine, Dentistry and Bio-medical Sciences Queen’s University Belfast, Belfast, UK, 3Lund University, Clinical Sciences, Division of Infection Medicine, Lund, Sweden, 4Lund University, Department of Biochemistry and Structural Biology, Center for Molecular Protein Science, Lund, Sweden, 5Malmö University, Department of Oral Biology, Faculty of Odontology, Malmö, Sweden, 6Malopolska Center of
P122  Dupilumab progressively suppresses inflammation, reduces epidermal hyperplasia and increases epidermal barrier gene expression in atopic dermatitis (AD) skin
Emma Guttman-Yassky1,2, Mayte Suárez-Fariñas1,2, Benjamin Ungar1,2, Brian Swanson4, Maria Suprun3, James Krueger2, Jonathan Silverberg5, Alan Menter6, Robert Bissonnette7, Marius Ardeleanu8, Jennifer Hamilton9
1Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, United States, 2Laboratory for Investigative Dermatology, The Rockefeller University, New York, United States, 3Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, United States, 4Sanofi, Bridgewater, United States, 5Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, United States, 6Menter Dermatology Research Institute, Dallas, United States, 7Innovaderm Research, Inc, Montreal, Canada, 8Regeneron Pharmaceuticals, Inc., Tarrytown, United States

P123  Impact of UVA on pruritus during UVA/B-phototherapy of inflammatory skin diseases - a randomized double-blind study
Julia-Tatjana Maul1, Lorenz Kretschmer1, Florian Anzengruber1, Carla Murer1, Lars E. French1, Günther F.L. Hofbauer1, Alexander A. Navarini1
1Department Of Dermatology, University Hospital Of Zurich, Zurich, Switzerland

P124  Current Status of Observations of Malignancies in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Study
David Fiorentino1, Mark Lebwohl2, Vincent Ho3, Richard Langley4, Kavitha Goyal5, Steve Fakharzadeh6, Steve Calabro5, Wayne Langhoff5
1Stanford University, Stanford, United States, 2Mount Sinai Medical Center, New York, United States, 3University of British Columbia, Vancouver, Canada, 4Dalhousie University, Halifax, Canada, 5Janssen Scientific Affairs, LLC, Horsham, United States

P125  Anti-inflammatory activity of a bacterial small molecule product derives from Aryl Hydrocarbon Receptor activation
Susan Smith1, Channa Jayawickreme1, David Rickard2, Edwige Nicodeme2, Thi Bui1, Cathy Simmons1, Christine Coquery1, Jessica Neil1, William Pryor1, David Mayhew1, Deepak Rajpal1, Katrina Creech1, Sylvia Furst1, James Lee1, Dalei Wu3, Fraydoon Rastinejad1, Timothy Willson3, Fabrice Viviani1, David Morris1, John Moore1, Javier Cote-Sierra1
1GlaxoSmithKline, RTP, United States, 2GlaxoSmithKline, Les Ulis, France, 3Sanford Burnham Prebys Medical Discovery Institute, Orlando, United States
P126 The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk markers
Patrick M. Brunner1, Mayte Suárez-Fariñas2, Helen He2, Jaehwan Kim1, Yeriel Estrada2, Batya Davidovici1, Nancy Dattola1, James G. Krueger1, Emma Guttman-Yassky2
1 The Rockefeller University, New York, United States, 2Icahn School of Medicine at Mount Sinai, New York, USA

P127 Precision medicine in psoriasis: Machine learning and proteomics join forces to develop a blood-based test to predict response to tofacitinib or Etanercept in psoriasis patients
Jaehwan Kim1, Joel Correa da Rosa1, Julie Lee2, Lewis Tomalin1, Michelle A Lowes1, Lori Fitz2, Gabriel Bernstein2, Hernan Valdez3, Robert Wolk3, James G Krueger1, Mayte Suárez-Fariñas4
1 The Rockefeller University, New York, United States, 2Pfizer Inc., Cambridge, United States, 3Pfizer Inc., New York, United States, 4Icahn School of Medicine at Mount Sinai, New York, United States

P128 Safety and efficacy of topical calcineurin inhibitors and topical steroids in atopic dermatitis in skin of color: a systematic review
Bridget Kaufman1, Andrew Alexis1
1 Mount Sinai St. Luke’s and Mount Sinai West, New York, United States

P129 Extended genome-wide association study in the United Kingdom revealing novel susceptibility loci for severe Acne vulgaris
Alexander A. Navarini1,2, United Kingdom Acne Consortium2
1 Department Of Dermatology, University Hospital Of Zurich, Zurich, Switzerland, 2 King’s College London, Division of Genetics and Molecular Medicine, London, United Kingdom

P130 Gentian Violet: A Potential Treatment For Cutaneous Leishmaniasis
Marc Karam1
1 University Of Balamand, Amchit, Lebanon

P131 Immune - Epidermal Stem Cell Interactions in Inflammatory Skin Disease
Samantha Larsen1, Nicholas Gomez1, Shruti Naik1,2, Elaine Fuchs1
1 Howard Hughes Medical Institute, Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Development, The Rockefeller University, New York, NY, 2 Damon Runyon Cancer Research Foundation Fellow, New York, NY USA
Differences between the microbiome of lesional and non-lesional skin in atopic dermatitis

M. Reiger¹, A.U. Neumann¹³, N. Garzorz-Stark², C. Altunbulakli³, K. Eyerich², C.A. Akdis³, C. Traidl-Hoffmann ¹

¹Chair and Institute of Environmental Medicine, UNIKA-T, Technical University of Munich and Helmholtz Zentrum München, Augsburg, Germany, ²Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany, ³Swiss Institute for Allergy and Asthma Research, University of Zurich, Davos Platz, Switzerland
Educational Grant Acknowledgement

This activity is made possible in part by educational grants from:

Amgen Inc.
Celgene Corporation
Demira, Inc.
Leo Pharma, Inc.
Valeant Pharmaceuticals North America LLC
Commercial Exhibition/Sponsorship

Platinum Sponsors

AbbVie Inc.
Pfizer Dermatology
Galderma
Janssen Biotech, Inc.
Lilly USA LLC
Regeneron Pharmaceuticals / Sanofi Genzyme

Gold Sponsors

Boehringer Ingelheim GmbH & Co. KG

Silver Sponsors

Novartis Pharmaceuticals Corporation
Pfizer, Inc.

Exhibitors

AbbVie Inc.
Pfizer Dermatology
Boehringer Ingelheim GmbH & Co. KG
Galderma
Janssen Biotech, Inc.
Lilly USA LLC
Novartis Pharmaceuticals Corporation
Pfizer, Inc.
Regeneron Pharmaceuticals / Sanofi Genzyme
## Industry Supported Sessions

### Complimentary CME Symposium

**WEDNESDAY, NOVEMBER 16, 2016 5:15 PM - 6:45 PM Hosack Hall**

**“Inflammation: More Than Skin Deep in Psoriasis”**

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit [www.lillygrantoffice.com](http://www.lillygrantoffice.com)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 5:15 pm – 5:20 pm | Introductions and Overview of Systemic Inflammation  
James G. Krueger, MD, PhD |
| 5:20 pm – 5:35 pm | Clinical Significance of Cardiometabolic Comorbidity in Psoriatic Disease  
Joel M. Gelfand, MD, MSCE |
| 5:35 pm – 5:50 pm | Pathogenic Mechanisms Linking Inflammatory Disease to Adverse Cardiometabolic Outcomes  
Iain B. McInnes, FRCP, PhD, FRSE |
| 5:50 pm – 6:05 pm | Current Treatment Paradigms of Moderate to Severe Psoriasis  
Joel M. Gelfand, MD, MSCE |
| 6:05 pm – 6:20 pm | Current Treatment Paradigms of Psoriatic Arthritis  
Iain B. McInnes, FRCP, PhD, FRSE |
| 6:20 pm – 6:35 pm | Translating Pathways to Clinical Cases  
Joel M. Gelfand, MD, MSCE & Iain B. McInnes, FRCP, PhD, FRSE |
| 6:35 pm – 6:45 pm | Questions and Answers |

### Complimentary Non-CME Symposium

**THURSDAY, NOVEMBER 17, 2016 8:00 AM – 9:30 AM Room 20**

**“Targeted mAb Therapies: Learning from the Past to Drive Innovation”**

AbbVie sponsored Symposium

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 8:00 am – 8:15 am | Introduction  
James Krueger, D. Martin Carter Professor in Clinical Investigation,  
The Rockefeller University |
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:15 am - 8:35 am</td>
<td>Through the Looking Glass of Targeted mAb Therapies</td>
<td>Maureen Kelly, Group Medical Director, Pharmaceutical Development, AbbVie</td>
</tr>
<tr>
<td>8:35 am - 9:00 am</td>
<td>Therapeutic Targeting of the IL-23 Axis: The Central Role of IL-23 in Psoriasis</td>
<td>James Krueger, D. Martin Carter Professor in Clinical Investigation, The Rockefeller University</td>
</tr>
<tr>
<td>9:00 am - 9:20 am</td>
<td>Engineering Therapeutic Antibodies - The Relationship of Structure to Function</td>
<td>Paul Tebbey, Therapeutic Area Lead, Biotherapeutics and Gastroenterology, US Medical Affairs, AbbVie</td>
</tr>
<tr>
<td>9:20 am - 9:30 am</td>
<td>Q&amp;A/Summary</td>
<td></td>
</tr>
</tbody>
</table>

Complimentary Non-CME Symposium

**THURSDAY, NOVEMBER 17, 2016 12:45 PM - 2:15 PM Room 20**

“Pathways to Personalized Medicine in Dermatology”
Speakers: Emma Guttman, MD, PhD & John Armstrong, PhD, Galderma Rx Strategic Programs
Galderma sponsored Symposium

Agenda: Please see separate brochure.

Complimentary CME Symposium

**FRIDAY, NOVEMBER 18, 2016 12:15 PM- 1:45 PM Hosack Hall**

“New Frontiers and Clinical Advances in the Pathoimmunobiology of Atopic Dermatitis”
Funded by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

12:15 pm - 12:30 pm The Disease Burden of Atopic Dermatitis: The Unmet Need for New Therapies in Patients with Moderate-to Severe and/or Resistant AD—The Rationale and Necessity for Intervening in the Atopic March and Mitigating the Risk of Co-Morbid Conditions
Emma Guttman, MD, PhD
Currently Established and Emerging Therapies for Managing Patients Across the Disease Continuum of Atopic Dermatitis: From Topical to Systemic Therapies—Guideline-Focused Sequencing Strategies From the AD Toolkit
Mark Lebwohl, MD

The Pathoimmunobiology of Atopic Dermatitis: Translating Advances in Immunoscience into Actionable Pharmacologic Targets for Treatment of Inflammatory Disorders of the Skin
Emma Guttman, MD, PhD

From Evidence to Clinical Action: Results and Translational Implications of Landmark Trials in Atopic Dermatitis: What Do the Trials Teach Us? What Are The Translational Implications for the Front Lines of Dermatology Practice?
Lisa A. Beck, MD

Question & Answer Session/Faculty Roundtable

Complimentary CME Symposium

FRIDAY, NOVEMBER 18, 2016 4:00 PM - 5:30 PM Hosack Hall

“Considerations for Future Treatment of Inflammatory Skin Disease: Immune Regulation, Cutaneous Tolerance, and T-cell Plasticity”
James G. Krueger, MD, PhD; Michael D. Rosenblum, MD, PhD; Vijay K. Kuchroo, PhD
Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. and Novartis Pharmaceuticals Corporation

Introduction: Tolerance, Immune Regulation, and Disease Interception

Tregs, Immune Regulation in the Skin, and Tolerance

T-cell Plasticity: A Focus on Th-17 T-cells

Q & A
Complimentary CME Symposium

SATURDAY, NOVEMBER 19, 2016  8:30 AM - 10:00 AM  Hosack Hall

“Advances in Atopic Dermatitis: Expert Insights Into New and Emerging Therapies”
This activity is supported by an educational donation provided by Anacor Pharmaceuticals, Inc.

8:30 - 9:00 am  Registration

9:00 - 10:00 am  Clinical Program
Amy S. Paller, MD

- Epidemiology and Comorbidity
- Pathophysiology
- Diagnosis and Assessment
- Treatment Guidelines
- Current Topical Approaches: Mild to Moderate Disease
- Current Systemic Approaches: Severe AD
- Emerging Therapies
- Summary
- Q & A
Targeted mAb Therapies: Learning from the Past to Drive Innovation

Thursday, November 17, 2016
The New York Academy of Medicine
Room 20
8:00–9:30 am

We are delighted to invite our ISDS colleagues to attend this interactive 90-minute breakfast symposium, which will review some of the key issues that surround the development and use of monoclonal antibodies as therapeutic tools. Presentation and discussion time will be dedicated to exploring the evolution of targeted monoclonal antibody therapy, molecular triggers of inflammatory disease, and the relationship between structure and function in engineered antibodies. Please join us and contribute your views.

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00–8:15 am</td>
<td>Introduction</td>
</tr>
<tr>
<td>8:15–8:35 am</td>
<td>Through the Looking Glass of Targeted mAb Therapies</td>
</tr>
<tr>
<td>8:35–9:00 am</td>
<td>Therapeutic Targeting of the Central Role of IL-23 in Psoriasis</td>
</tr>
<tr>
<td>9:00–9:20 am</td>
<td>Engineering Therapeutic Antibodies – the Relationship of Structure</td>
</tr>
<tr>
<td>9:20–9:30 am</td>
<td>Q&amp;A and Summary</td>
</tr>
</tbody>
</table>

Supported by

This event is neither sponsored by nor endorsed by the Icahn School of Medicine
We are delighted to invite our ISDS colleagues to attend this interactive 90-minute breakfast symposium, which will review some of the key issues that surround the development and use of monoclonal antibodies as therapeutic tools. Time will be dedicated to exploring the evolution of targeted monoclonal antibodies in inflammatory disease, and the relationship between structure and function in engineered antibodies. Please join us and contribute your views.

**Faculty**

James Krueger  
*D. Martin Carter Professor in Clinical Investigation*  
The Rockefeller University

Maureen Kelly  
*Group Medical Director*  
Pharmaceutical Development  
AbbVie

James Krueger  
*D. Martin Carter Professor in Clinical Investigation*  
The Rockefeller University

Paul Tebbey  
*Therapeutic Area Lead*  
Biotherapeutics and Gastroenterology  
US Medical Affairs  
AbbVie

All

---

Breakfast available from 7:30 am
Before it became a medicine,

It was 5,000 researched compounds.

87 different protein structures.

500,000 lab tests.

1,600 scientists.

80-hour workweeks.

14 years of breakthroughs and setbacks.

36 clinical trials.

8,500 patient volunteers.

And more problems to solve.

Before it became a medicine,

It was an idea in the mind of a Pfizer scientist.

Now it’s a medicine

That saves lives every day.
Before it became a medicine,

...searched compounds.

...protein structures.

...lab tests.

...scientists.

...workweeks.

...roughs and setbacks.

...clinical trials.

...patient volunteers.

...solve than we could count.

Before it became a medicine,

...of a Pfizer scientist.

...medicine

...es every day.
Pathways to Personalized Medicine in Dermatology

THURSDAY, NOVEMBER 17, 2016, 12:45 – 14:15 (Room 20)
THE NEW YORK ACADEMY OF MEDICINE, NYC, USA

Presenting the historical pathways that have led to the practice of personalized medicine in several branches of medicine, followed by a presentation of how the practice of translational medicine is bringing dermatology into the world of personalized medicine.

A COMPANY-SPONSORED SYMPOSIUM
Hosted by Galderma
SPEAKERS

Emma Guttman-Yassky, MD, PhD, professor of dermatology and immunology, is vice chair for research at the department of dermatology, director of the Center for Excellence in Eczema, and the Laboratory of Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai Medical Center, New York. She earned her M.D. from Sackler in Tel-Aviv, and a Ph.D. from Bar-Ilan, Israel. After her Israeli Board certification in dermatology, Dr. Guttman moved to the U.S. to pursue a postdoctoral fellowship at The Rockefeller University and a second dermatology residency at Weill-Cornell, NY. Dr. Guttman's major focus is atopic dermatitis/AD. She made paradigm-shifting discoveries on the immunologic basis of AD in humans, enriching the understanding of its pathophysiology, and opening the door to new therapeutics. Dr. Guttman has developed comprehensive molecular maps of AD, defining skin differentiation and immune-circuits characterizing this disease. She has established the reversibility of the AD phenotype and defined a series of biomarkers that are now accelerating testing of novel pathway-specific drugs for AD. She is now testing (both clinically and mechanistically) multiple targeted therapeutics for atopic dermatitis that target Th2, Th22, and Th17/IL-23 axis. She has recently also extended her research interest to alopecia areata in which her findings are also translated to possible novel therapeutic targets. She has co-founded the international eczema council/IEC, for which she functions as president-elect. She was elected to the American Society for Clinical Investigation/ASCI, the American Dermatological Society/ADA, and received the Young Investigator Award (2011) from the AAD.

John M. Armstrong, PhD is the Director of Strategic Programs for the Prescription Business Unit at Galderma International in Paris, France. After earning his PhD in Immunology at UT Southwestern Medical Center at Dallas, he completed his first post-doctoral fellowship studying differences in drug biotransformation between different ages, genders, strains, and species at Sandoz Pharmaceutical Company in Basel, Switzerland, and his second post-doctoral fellowship studying signal transduction pathways in animal models of immunodeficiency at the US National Institutes of Health in Bethesda, Maryland. In addition to working in Medical Affairs at Bayer Health Sciences and at Johnson and Johnson, in 2006 Dr. Armstrong co-founded Lead Horse Technologies, a personalized medicine company. As Chairman & CEO, he led a team of scientists and physicians applying big data analytics to millions of real-world patient records to quantify the individual risk of adverse event development in patients with diverse medical profiles.
If you are a US medical doctor with an active state license number, the value of the food, beverage, and/or educational item that you receive when attending this program may be disclosed on Eli Lilly and Company's Physician Payment Registry and/or the National Physician Payment Transparency Program (NPPTP) Open Payments report under the federal Sunshine Act as a transfer of value made to you by Lilly. As a result of enacted state regulations, food and beverages will not be provided to healthcare professionals licensed in the states of Minnesota, Massachusetts, and Vermont. Additionally, educational items will not be provided to healthcare professionals licensed in Minnesota. Federal Veterans Affairs (VA) regulations and several states also prohibit state/government employees from receiving or being provided gift items, which may include educational materials and meals. Please consult your state regulations and ethics laws to see if such prohibition would apply to you. This medical presentation is intended only for invited healthcare professionals for whom the information to be presented is relevant to their practice. We regret that spouses or other guests cannot be accommodated. This is a promotional program and no continuing medical education (CME) credits are offered.

Taltz® is a registered trademark of Eli Lilly and Company.
PP-IX-US-0821 08/2016 ©2016, LILLY USA, LLC. ALL RIGHTS RESERVED.
If you are a US medical doctor with an active state license number, the value of the food, beverage, and/or educational item that you receive when attending this program may be disclosed on Eli Lilly and Company’s Physician Payment Registry and/or the National Physician Payment Transparency Program (NPPTP) Open Payments report under the federal Sunshine Act as a transfer of value made to you by Lilly. As a result of enacted state regulations, food and beverages will not be provided to healthcare professionals licensed in the states of Minnesota, Massachusetts, and Vermont. Additionally, educational items will not be provided to healthcare professionals licensed in Minnesota. Federal Veterans Affairs (VA) regulations and several states also prohibit state/government employees from receiving or being provided gift items, which may include educational materials and meals. Please consult your state regulations and ethics laws to see if such prohibition would apply to you. This medical presentation is intended only for invited healthcare professionals for whom the information to be presented is relevant to their practice. We regret that spouses or other guests cannot be accommodated. This is a promotional program and no continuing medical education (CME) credits are offered.
IN ATOPIC DERMATITIS, LOOKS CAN BE DECEIVING

DISCOVER THE INFLAMMATION BENEATH.

Current evidence suggests that nonlesional skin is not normal skin because of persistent underlying inflammation throughout the body. In fact, this persistent underlying inflammation is a source of lesions and itch, the primary signs and symptoms of atopic dermatitis.

The Th2 cytokines IL-4 and IL-13 are key drivers of the underlying inflammatory process.

Sanofi Genzyme and Regeneron are committed to research in atopic dermatitis.

References:
Boehringer Ingelheim Immunology
Pipeline for the treatment of autoimmune diseases

<table>
<thead>
<tr>
<th>Compound</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>BI 695501</td>
<td></td>
<td></td>
<td></td>
<td>Autoimmune diseases</td>
</tr>
<tr>
<td>Adalimumab biosimilar candidate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nintedanib</td>
<td></td>
<td></td>
<td></td>
<td>Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)</td>
</tr>
<tr>
<td>Tyrosine Kinase inhibitor targeting VEGF, FGF and PDGF pathways</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCE</td>
<td></td>
<td>Systemic Lupus Erythematosus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCE</td>
<td></td>
<td>Psoriasis, Psoriatic arthritis, Ankylosing spondylitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BI 655064</td>
<td></td>
<td>Immune thrombocytopenia</td>
<td>Rheumatoid arthritis, Lupus nephritis</td>
<td></td>
</tr>
<tr>
<td>CD40 antagonist mAb</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NBE</td>
<td></td>
<td>Ulcerative colitis</td>
<td>Psoriasis</td>
<td></td>
</tr>
<tr>
<td>NBE</td>
<td></td>
<td>Psoriatic arthritis, Crohn’s disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NBE</td>
<td></td>
<td>Lupus nephritis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NBE=new biological entity; NCE=new chemical entity; IL-23=Interleukin-23; mAb=monoclonal antibody

These compounds are either investigational or studied in new indications or populations. Their safety and efficacy have not been established.

If you are a healthcare professional who may be interested in becoming a clinical investigator, please visit: www.clinicaltrials.gov.
Jointly provided
by the Kimberly and Eric J. Waldman Mount Sinai Department of Dermatology
and the Austrian Academy of Sciences.

www.isds2016.org